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Chapter 1 
Introduction 
Chapter 1 
The hepatitis B virus 
The hepatitis B virus (HBV) is a DNA virus that belongs to the group ofhepadnaviridae. The partially 
double-stranded DNA contains 4 open reading frames, encoding for the envelope (pre-S/ S), core 
(precore/ core), polymerase and X proteins (1). The pre-S/S open reading frame encodes for the large, 
middle and small surface glycoproteins. The precore/ core region encodes for both the nucleocapsid 
protein (hepatitis B core antigen) and a soluble protein, the hepatitis B e antigen (HBeAg). After 
attachment of HBV to the hepatocyte, the viral genome is converted into covalently closed circular 
DNA (cccDNA) within the hepatocyte nucleus (Figure 1). This cccDNA serves as template for the 
pregenomic mRNA. In the hepatocyte cytoplasm viral particles are assembled from HBV core protein, 
HBV DNA polymerase and the pregenomic mRNA. Within these particles the pregenomic mRNA is 
reverse transcribed by the HBV DNA polymerase into the minus strand HBV DNA. Finally the plus 
strand DNA is synthesized by the HBV DNA polymerase (2). There are seven major HBV genotypes 
(A to G), prevailing in different parts of the world (3-6). Recently another genotype, genotype H, was 
found in central America (7). 
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Fig 1 The replication cycle ofthe hepatitis B virus 
Chronic hepatitis B 
HBV polymerase 
protein 
An estimated 400 million people worldwide are chronically infected with HBV (8). Chronic hepatitis 
B can lead to serious morbidity and mortality and is a major cause of liver cirrhosis and liver cancer 
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(8-12). HBV is transmitted by perinatal, sexual and percutaneous exposure and also by close 
household contact, especially among children in endemic areas. In countries with high prevalence of 
the disease (>8%), mainly Southeast Asia, China and sub-Saharan Africa, the disease is transmitted 
perinatally or during early childhood. In Northwestern Europe, North America and Australia, where 
the prevalence of chronic HBV infection is low (<1 %), the main source of infection is sexual contact 
and through intravenous drug use. In the Mediterranean countries, the Middle East and India, areas 
with intermediate endemicity (1-8%) perinatal, household and sexual transmission were the major 
sources of infection in the past. These days intravenous drug use, nosocomial transmission, tattooing 
and body piercing are becoming important modes of transmission (13). After infection with HBV, the 
risk of chronicity varies with the age at which the infection is acquired. The risk of the infection 
becoming chronic is 90% for neonates and children younger than 1 year, 30 % for children aged 1-5 
years, and 2% for children older than 5 years and adults (14). Three phases of chronic hepatitis B have 
been described (13, 15, 16). Patients who acquire the infection during childhood start with a long 
immune tolerance phase with detectable serum HBeAg, high levels of serum HBV DNA, normal or 
minimally elevated serum aminotransferases and near normal liver histology. This phase is followed 
by an immunoclearance phase, which is the frrst phase for patients who acquire the infection during 
adolescence or as adults. In this phase the host's immune system is activated in an attempt to eliminate 
the virus. As a result of this immune activation serum aminotransferases arc elevated, serum 1-IBV 
DNA levels decrease and liver histology shows active inflammation and fibrosis. This phase ends 
when HBeAg seroconversion and a dramatic reduction of HBV DNA occurs. Finally, there is an 
inactive phase (also called inactive carrier state) with undetectable serum HBeAg, normal serum 
transaminases, low or undetectable serum HBV DNA and resolution of necroinflammion. This may 
lead to resolution of the infection with HBsAg seroconversion. However, patients may show 
persistence or recurrence of disease activity and continue to HBeAg-negative chronic hepatitis B, 
particularly patients who acquired the disease during childhood. This thesis focuses on patients with 
HBeAg-positive chronic hepatitis B, who are in the immune clearance phase of the infection. 
Management of chronic hepatitis B 
1. Nucleoside/nucleotide analogues 
Nucleos(t)ide analogues are able to suppress viral replication by inhibiting the HBV polymerase. Two 
drugs in this group have been approved for the treatment of chronic hepatitis B: larnivudine and 
adefovir dipivoxil. 
Lamivudine is a nucleoside analogue of deoxycytidine, the (negative) enantiomer of 2'-deoxy-3'-
thiacytidine. One year of larnivudine treatment results in HBeAg seroconversion in 16-18% of 
patients, suppression of HBV DNA to below detection level of hybridisation assays in almost all 
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patients, and improved liver histology in 49-56% of patients (17-19). Prolonged treatment leads to a 
sustained improvement of liver necroinflammation and has been shown to substantially improve 
fibrosis and even reverse cirrhosis in some patients (20, 21). However the efficacy of larnivudine 
treatment is limited by the emergence of lamivudine resistant strains that harbor mutations that affect 
the YMDD region of the HBV DNA polymerase. These 1arnivudine resistant mutants are found in an 
increasing frequency over time, which rises to 70-71% of patients after 4 years of larnivudine 
treatment (22, 23). Irrespective of the YMDD mutation relapse occurs after discontinuation of 
treatment in a proportion of patients, with reported relapse rates varying from 31-42% at 1 year and 
46-64% at 3 years posttreatment (24-26). The optimal timing of stopping treatment is unknown, but 
the risk of relapse is lower if treatment is continued for 3-4 months after HBeAg-seroconversion (24). 
Adefovir dipivoxil, an acyclic analogue of adenosine monophosphate, has recently been approved for 
the treatment of CHB. In a large international study, one year of adefovir therapy resulted in a strong 
suppression ofHBV DNA (median reduction ofHBV DNA 3.5 log, HBV DNA undetectable by PCR 
in 21% of patients), improved liver histology in 53% of patients and HBeAg seroconversion in 12% of 
patients (27). Adding adefovir to larnivudine in patients with larnivudine resistance resulted in 
virological and biochemical improvement in two studies involving patients with compensated liver 
disease, decompensated cirrhosis or recurrent CHB after liver transplantation (28, 29). In a pilot study 
of 58 patients with YMDD mutant hepatitis B virus, adefovir alone was as effective in suppressing 
HBV DNA as combination therapy oflarnivudine and adefovir. 
2. Interferon alpha (IFN) 
In chronic hepatitis B IFN has a dual mode of action with direct antiviral and immunomodulatory 
effects. A meta-analysis (30) of 498 patients, treated with IFN for 3-6 months and followed up for 6-
12 months, showed that IFN induced loss ofHBeAg, HBV DNA (measured by hybridisation assays) 
and HBsAg in 33%, 37% and 8% of patients, respectively. The corresponding figures for untreated 
controls were 12%, 17% and 2%, respectively (p<0.01). The major pre-treatment factors that have 
been found to be associated with response are high ALT levels, low HBV DNA levels and a higher 
degree of inflammation and fibrosis on liver biopsy. Studies in Asian patients show less favourable 
results than in Caucasians (30, 31). This might be explained by the fact that most Asian patients 
acquire the HBV infection at birth and are immune tolerant to HBV. In a study with 411 Chinese 
patients, the response rate 6 months posttreatment was only 11.5%, but 21% for patients with elevated 
(>1.5 ULN) ALT levels (32). 
The optimal duration of IFN therapy has not been established. A European multicenter trial with 162 
patients showed that prolongation of therapy from 16 to 32 weeks had additional benefit in patients 
who had not cleared HBeAg after 16 weeks of therapy. A low HBV DNA level after 16 weeks of 
therapy predicted response during prolonged therapy (33). 
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Long-term follow-up studies with Caucasian patients showed that 91%-100% of responders remained 
HBeAg negative during 5-10 years of follow-up, and 25%-86% of responders ultimately lost HBsAg 
(34-37). In a study with 411 Chinese patients the rate of HBeAg relapse was higher and after long-
term follow-up the proportion of patients with HBeAg loss was not different between IFN-treated 
patients and untreated controls (32). In a study with Taiwanese patients, who had high ALT levels 
(mean ALT 227 UIL), similar results were found as in Caucasian patients (38). The response rate was 
42%, and response was sustained in 89% of patients during long-term follow-up. 
With the current established therapies, IFN and lamivudine, only a minority of patients respond. 
Possible ways to increase efficacy are: 
Prolongation of therapy 
Prolonging IFN therapy to 32 weeks has been shown to improve response rates in patients 
who are still HBeAg positive after 16 weeks of therapy (33). Prolonging the duration of IFN 
therapy to 52 weeks may further increase the efficacy of treatment. 
Combination therapy ofiFN and lamivudine 
It seems logical to combine the immunestimulatory effects of IFN with the virussuppressive 
action of lamivudine. The combination of 16 weeks of IFN and lamivudine appears to be 
superior to IFN alone (19). Also the sustained response after 24 weeks of treatment with IFN 
and lamivudine was higher than after one year oflamivudine alone (39). 
Using pegylated forms of IFN with an improved pharmacokinetical profile 
At the start of this study pegylated forms of IFN were being investigated in patients with 
chronic hepatitis B, and the first study showed promising results. Now, pegylated interferons 
have shown to be more effective than conventional IFN and have become the standard therapy 
in chronic hepatitis C (40-44). In a first study in patients with chronic hepatitis B, pegylated 
IFN-2a was more effective than conventional IFN based on combined HBeAg loss, HBV 
DNA suppression below 50000 copies/ml andALT normalization (45). 
The aims of this study are: 
1. To evaluate the safety and efficacy ofpegylated interferon alpha-2b alone or in combination 
with lamivudine for the treatment of chronic hepatitis B (chapters 2-5). 
2. To study the long-term clinical outcome and survival after treatment with standard IFN for 
chronic hepatitis B (chapter 6). 
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Abstract 
Background: Current treatment ofHBeAg-positive chronic hepatitis B (CHB) patients is effective in 
few patients. A combination of immunomodulatory peginterferon a2b and antiviral lamivudine may 
enhance the sustained response rate. 
Methods: 266 interferon-naive and -experienced HBeAg-positive CHB patients were randomized to 
receive combination therapy with 100 J..lg/week peginterferon a-2b and 100 mg/day lamivudine or 
monotherapy with 100 J..lg/week peginterferon a-2b and placebo. Total treatment duration was 52 
weeks. During Weeks 32-52 the peginterferon dose was reduced to 50 J..lg/week in both treatment 
arms. All patients were followed up for 26 weeks after treatment. 
Results: 36% of patients receiving monotherapy and 35% receiving combination therapy lost HBeAg 
after the end of follow up and there was no difference between treatment groups (P=0.91). More 
patients on combination therapy initially cleared HBeAg (44% of patients, compared with 29% on 
monotherapy; P=O.Ol) at the end of treatment but relapsed during follow-up. Similar response patterns 
were seen when response was assessed by serum HBV DNA suppression and change in ALT levels. 
Response rates (HBeAg loss) varied by genotype (P=0.01): genotype A, 47%; genotype B, 44%; 
genotype C, 28%; and genotype D, 25%. 
Conclusions: Peginterferon a-2b treatment is effective for HBeAg-positive CHB and combination 
therapy with peginterferon a-2b and lamivudine is not superior to monotherapy. HBV genotype is an 
important predictor of response to treatment. 
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Introduction 
Patients successfully treated for chronic hepatitis B (CHB) are less likely to develop cirrhosis, liver 
failure and hepatocellular carcinoma (1,2), however, to date, treatment for CHB has been unsuccessful 
in the majority of patients. Of the few currently approved agents for treatment of chronic hepatitis B 
virus (HBV) infection, the most commonly used include interferon-a and nucleos(t)ide analogues, 
such as lamivudine and adefovir dipivoxil. 
In early studies, standard (non-pegylated) interferon-a treatment reportedly cleared HBeAg and HBV 
DNA in approximately one-third of treated patients (1,2). More recently, response rates of only 19% 
have been noted (3). Interferon-a-induced HBeAg clearance has been reported to be durable in 80%-
90% of patients and the clearance is associated with a reduction of hepatocellular carcinoma and death 
(4-7). 
DNA polymerase inhibitors, of which larnivudine and adefovir dipivoxil are currently the most 
effective and studied, achieve profound virus load reduction (8,9). However, sustained response after 
treatment discontinuation is as yet unknown for adefovir dipivoxil and occurs in only 1 0-15% of 
patients treated with larnivudine (1 0). Durability of lamivudine response has been found to be 
significantly lower than that following interferon-a therapy (11). Furthermore, the long-term efficacy 
of nucleoside analogues is compromised by the almost inevitable emergence of drug-resistant HBV 
mutants, a scenario analogous to the antiretroviral experience (12). Larnivudine resistance has been 
reported in 57% of patients after 3 years of treatment (13). 
There is increasing evidence that only a complete and vigorous REV-specific immune response is 
capable of achieving control and elimination of the virus, preventing disease progression (14). This 
suggests that induction of a host immune response is necessary for sustained response to HBV 
treatment, which can only be reached by imrnunomodulatory therapy, such as interferon. 
The introduction of pegylated interferons (peginterferons) in the treatment of hepatitis C has led to 
greater treatment efficacy than that achieved with standard interferon (15), and a preliminary study has 
been conducted in the treatment of CHB (16). Increased efficacy with peginterferons may be due to 
more continuous levels of interferon in the serum than that achieved with standard interferon. The 
improvements in efficacy are combined with a similar safety profile and simpler and more convenient 
dosing (once weekly) compared with standard interferon (TIW). The convenience of dosing is 
significant because, across the therapeutic spectrum, simplified dosing regimens have been shown to 
enhance compliance, which in turn increases treatment efficacy (17). 
To date, most studies of standard interferon combination regimens for the treatment of HBV disease 
have investigated the efficacy of 16-week regimens (3,18). However, studies indicate that prolonged 
regimens may result in higher rates of sustained response for the treatment of HBV disease (19). This 
study is based on the rationale that combining the immunomodulatory properties of interferon and the 
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strong antiviral potency of lamivudine in a prolonged treatment regimen may enhance the sustained 
response rate in CHB. This is the first study to assess whether prolonged treatment with peginterferon 
a-2b, alone or in combination with lamivudine, can improve sustained treatment response in patients 
with HBeAg-positive CHB. 
Methods 
Patients 
Patients with CHB aged 16 years or over were enrolled after central evaluation of their eligibility. 
Patients were included if they were positive for hepatitis B surface antigen (HBsAg) for more than six 
months, were HBeAg positive on two occasions within 8 weeks before randomization and had two 
episodes of elevated serum ALT levels (2 X upper limit of normal) within the 8 weeks before 
randomization. Patients were excluded for the following reasons: presence of serum antibodies against 
hepatitis C, hepatitis D or human immunodeficiency virus; antiviral therapy or immune suppressive 
therapy within the preceding 6 months; pregnancy or inadequate contraception; substance abuse in the 
last 2 years; other acquired or inherited causes of liver disease; coexisting serious medical or 
psychiatric illness; uncontrolled thyroid disease; inadequate level of leukocytes (:S3,000/=3), 
granulocytes (:Sl,8001=\ or platelets (:Sl00,000/=3); radiological evidence of hepatocellular 
carcinoma; advanced liver disease with a prothrombin time prolonged by more than 3 seconds, serum 
albumin under 35 g/1, bilirubin more than 34 J.Lg/L, or a history of either ascites, variceal bleeding and 
hepatic encephalopathy. 
Study design 
This was an investigator-initiated, multicenter, randomized, double-blind controlled trial conducted at 
42 centers in 15 countries (in Europe, East Asia and North America). Recruitment began in February 
2000 and the study ended in October 2003. The study compared the efficacy and safety of 
peginterferon a-2b monotherapy with peginterferon a-2b and larnivudine combination therapy for 
treatment of patients with HBeAg-positive chronic HBV infection. Patients were randomly assigned in 
a 1:1 ratio to receive combination therapy with weekly doses of 100 Jlg peginterferon a-2b (Peglntron, 
Schering-Plough) and 100 mg lamivudine (Zefflx, GlaxoSmith.Kline) daily or monotherapy with 100 
J.Lg/week peginterferon a-2b and placebo. Total duration of treatment was 52 weeks. To limit the 
probability of early treatment discontinuation peginterferon was reduced to a dose of 50 J.Lg/week in 
both treatment arms after 32 weeks. Patients with :S 55 kg body weight received weight-adjusted 
dosing of peginterferon a-2b of 1.5 Jlglkg/week for the first 32 weeks and 0.75 J.Lg/kg/week for the 
remainder of the treatment period. All patients were followed-up for 26 weeks after treatment. During 
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treatment and follow-up patients attended the outpatient clinic every 4 weeks for routine examination 
and laboratory assessments. Patients were randomized centrally and stratified according to 
investigational center. Treatment was allocated in blocks of six per center. The study was conducted in 
accordance with the Declaration of Helsinki and formally approved by the ethical committee of each 
participating centre. Patients were required to give their written, informed consent before entering the 
study. Predefmed data entry and data analysis were performed at the Clinical Research Unit of the 
coordinating center at the Erasmus MC, Rotterdam. The sponsor of this study was the Rotterdam 
Foundation for Liver Research (SLO). 
Evaluation 
Outcome measures were assessed at the end of treatment (yY eek 52) and at the end of follow-up (yY eek 
78). The primary outcome measure was loss of HBeAg from serum (AxSYM, Abbott). Secondary 
outcome measures were HBV-DNA levels below 200,000 copies/ml, HBV-DNA below the level of 
detection, which was 400 copies/ml (in-house Taqman PCR assay based on the Eurohep standard) (20) 
, ALT normalization and presence of mutations in the YMDD motif of HBV polymerase (Inno-Lipa 
assay; Innogenetics). HBsAg (AxSYM, Abbott) and genotype (Inno-Lipa assay; Innogenetics) were 
also assessed. Routine biochemical and hematological tests were performed at the participating centers 
using automated techniques. To correct for heterogeneity of local assays, levels of serum ALT were 
expressed as values representing a ratio to the local upper limit of normal (ULN). All HBV markers 
were assessed centrally. Liver histology was assessed at baseline and an optional biopsy was taken at 
the end of treatment. The biopsies were scored centrally by one experienced pathologist who was 
blinded to the treatment regimen and chronological order of the biopsy. Histological scoring was 
performed according to the histological activity index, as described by Ishak (21). Improvement of 
histology was defmed as a reduction of at least two points for the necroinflammatory score (range 0--
18) and one point for the fibrosis score (range 0-6). 
Statistical analysis 
The study was powered to account for a mixed population with 50% of patients previously non-
responsive to interferon therapy and 50% interferon-naive, with a baseline ALT level of >2 X ULN. 
To obtain a power of greater than 80% (a=0.05), an estimated 270 patients needed to be included, 
assuming HBeAg loss at end of follow up of 20% for peginterferon a-2b monotherapy versus 36% for 
lamivudine combination therapy. The sample size calculation was based on an estimated drop out rate 
of 20%, which were to be considered as treatment failures. The effect of peginterferon a-2b 
monotherapy and combination therapy with lamivudine on response rates were compared by the ·£ 
test. Response rates are those assessed by percentage HBeAg loss, HBV-DNA below 200,000 
copies/ml, HBV-DNA negative by PCR or ALT normalization at the end of treatment and end of 
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follow-up. A response was considered to be significantly different between the two treatment groups if 
it achieved a 0.05 level of significance (X2 test). Patients with missing data at Week 52 or at Week 78 
were regarded as nonresponders at end of treatment and end of follow up, respectively. The 
relationship between the patients' baseline characteristics and HBeAg loss at end of follow up 
(sustained response) was examined by logistic regression analyses. Univariate analysis was used to 
assess the importance of prognostic factors. To determine the independence of these factors, multiple 
logistic regression analyses were performed using all baseline characteristics given in table 1. All P 
values were two sided. 
Results 
Patient demographics 
Of the 307 patients who met the entry criteria and were randomized to receive peginterferon a-2b and 
lamivudine combination therapy or peginterferon a-2b and placebo, 266 were included in the final 
modified intent-to-treat analysis (figure 1). 
307 patients randomly 
allocated to treatment 
15 5 allocated to treatment with 
peginterferon a-2b and placebo 
3 never started treatment 
14 discontinued therapy early 
(all because of side effects) I+--
8 lost to follow-up 
13 6 analyzed 
19 excluded from analysis: 
- no treatment (3) 
- HBeAg negative at the start of 
treatment ( 4) 
-no source data verification (12) 
152 allocated to treatment with 
peginterferon a-2b and lamivudine 
4 never started treatment 
14 discontinued therapy early 
(13 because of side effects, 
~ 1 for unknown reasons) 
4 lost to follow-up 
13 0 analyzed 
22 excluded from analysis: 
- no treatment ( 4) 
- HBeAg negative at the start of 
treatment ( 6) 
- no source data verification (12) 
Figure 1. Flow diagram of patients through each stage ofthe study 
24 
PEG-IFN treatment for chronic hepatitis B 
Patients were excluded from the fmal analysis if they were, in retrospect, HBeAg negative at the start 
of treatment (n=10), if they did not take any study medication (n=7), and patients recruited by one 
center were excluded because the source data could not be verified (n=24). Patients excluded from the 
fmal analysis were equally distributed among assigned treatment groups. Fewer interferon-experienced 
patients were recruited than expected (21 %); therefore, with the total of 266 patients in the modified 
intent-to-treat group, the study remained more than adequately powered. All patients in the final 
analysis were comparable with respect to baseline demographics and disease characteristics (table 1). 
Table I. Baseline disease characteristics of the modified intent-to-treat population 
Characteristic 
Age (year); mean± SD 
Sex: male, n (%) 
Weight (kg); mean± SD 
Ethnic background, n (%) 
Caucasian 
Asian 
Other/Mixed 
Transmission, n (%) 
Vertical 
Sexual I parenteral 
Unknown 
AL T X ULN (U/l); mean± SD 
Log HBV DNA ( copies/ml); mean± SD 
Genotype, n (%) 
A 
B 
c 
D 
Other 
Cirrhosis, n (%) 
Previous interferon therapy, n (%) 
Previous lamivudine therapy, n (%) 
Peginterferon-o: 2b 
+lamivudine (n=130) 
34± 12 
98 (75) 
74± 16 
98 (73) 
32 (18.5) 
11 (8.5) 
29 (22) 
32 (25) 
69 (53) 
4.4 ± 3.9 
9.1 ± 1.0 
43 (33) 
11 (9) 
18 (14) 
52 (40) 
6(4) 
13 (12) 
27 (21) 
17 (13) 
Peginterferon-o: 2b 
+placebo (n=136) 
36± 14 
107 (79) 
72±13 
101 (74) 
29 (21) 
6 (4) 
31 (23) 
33 (24) 
72 (53) 
4.3 ± 3.1 
9.1 ± 0.8 
47 (35) 
12 (9) 
21 (15) 
51 (38) 
5(4) 
11 (10) 
28 (21) 
16 (12) 
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HBeAg response 
As summarized in table 2, the response at the end of treatment (Week 52), as assessed by serum 
HBeAg loss, was greater in the combination therapy group (44% of patients), compared with the 
monotherapy group (29%; P=O.Ol). However, this differential was not sustained at the end of follow 
up (Week 78). Peginterferon a-2b monotherapy resulted in a response rate of 36% after the end of 
follow up but only 35% of patients had a sustained response to peginterferon a-2b and lamivudine 
combination therapy (P=0.91). 
HBV-DNA response 
At the end of treatment, more patients (74%) had HBV DNA levels suppressed to below 200,000 
copies/ml in the group treated with combination therapy than in those treated with peginterferon a-2b 
alone (29%; P<O.OOl) (table 2). The higher levels ofHBV DNA suppression achieved in the patients 
treated with larnivudine combination therapy were not sustained over the follow-up period, with 32% 
of patients retaining HBV DNA suppression in the combination group, compared with 27% in the 
group treated with peginterferon a-2b monotherapy (P=0.44). Similarly, when patients with 
undetectable HBV DNA (HBV negativity by PCR) were assessed, although more patients on the 
combination therapy than on monotherapy initially responded at the end of treatment (33% compared 
with 10%; P<O.OOl), at the end of follow up there was no difference between the treatment groups (9% 
compared with 7%; P=0.43) (table 2). These response patterns were also reflected by longitudinal 
serum HBV DNA levels, which revealed greater reduction of viral load in the group treated with 
combination therapy than those on monotherapy, followed by a post-treatment rebound ofHBV DNA 
only for those treated with combination therapy (figure 2). 
ALT response 
The response assessed by ALT levels followed a similar pattern to HBV DNA suppression and loss of 
HBeAg (table 2). At the end of follow-up, there was no difference in response between patients treated 
with monotherapy (32% of patients responded) and those treated with combination therapy (35%; 
P=0.60) despite a difference at the end of treatment (34% compared with 51%; P=0.005). 
HBsAg response 
There was no difference in the proportion of patients with HBsAg loss between the treatment groups at 
the end of treatment and at the end of follow up (table 2). At the end of follow up 7% of patients in 
both groups had HBsAg loss (P=0.92). 
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Treatment 
PEG-IFN and placebo 
4 
16 24 32 40 48 56 64 72 80 
Week 
Patients evaluated 
PEG-IFNI 130 125 127 121 122 117 119 108 104 108 108 
Placebo 
PEG-IFNI 125 123 120 113 118 115 104 109 104 100 107 
lamivudine 
Figure 2. Serum levels of hepatitis B virus DNA (HBV DNA) 
Histological response 
Data on the change in histology of the liver from before treatment to the end of therapy were available 
for 110 patients (biopsies at the end of treatment were optional). Fibrosis scores improved in 33% of 
patients on combination therapy and 22% of patients on monotherapy (P=0.22; table 2). With respect 
to inflammatory changes in the liver, there was little difference between the two treatment groups. 
Improvements were seen in 48% of patients on combination therapy at the end of treatment and 53% 
of patients on monotherapy (table 2). 
Lamivudine resistance 
Of the 130 patients treated with combination therapy (patients who received lamivudine), 14 (11 %) 
patients had the YMDD mutant at the end of treatment Two patients responded to therapy with loss of 
HBeAg. Seven of them had been previously treated with lamivudine and harbored a mutant from the 
28 
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start of therapy. 
Response by genotype 
There was a significant difference in sustained response rate according to HBV genotype (by 
univariate analysis, P=O.Ol). For patients with genotype A, 47% lost HBeAg at the end of follow up, 
44% of patients with genotype B responded, compared with 28% with genotype C and 25% with 
genotype D (figure 3). There was no difference in HBeAg loss according to HBV genotype between 
the two treatment groups. To assess the independence of genotype as a prognostic factor, multivariate 
analysis was performed. With this analysis, the odds ratios show that patients infected with genotype A 
are more likely to respond to treatment than those with genotype D (odds ratio: 2.4, 95% CI 1.3-4.6, 
P<O.Ol) or C (odds ratio: 3.6, 95% CI 1.4-8.9, P<O.Ol). There was a trend for patients infected with 
genotype B to be more likely to respond than those with genotype C (odds ratio: 2.2, 95% CI 0.7-7.0, 
P=0.18). Other baseline factors that were predictive of response with multivariate analysis were low 
viral load (odds ratio: 1.6, 95% CI 1.3-1.8, P<O.Ol), high ALT levels (odds ratio: 1.1, 95% CI 1.0-1.2, 
P=0.02), and absence of prior interferon therapy (odds ratio: 2.2, 95% CI 1.1-4.5, P=0.04). 
60 
50 47 44 
40 
30 
20 
10 
0 
A B c D 
n=90 n=23 n=39 n=103 
HBV Genotype 
Figure 3. Proportion of patients responding to treatment (serum HBeAg loss) by HBV genotype. 
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Safety 
With respect to safety and tolerability, there was no difference between patients treated with 
peginterferon a-2b alone and those treated with peginterferon a-2b and lamivudine combination 
therapy. The side effect profile was similar to that seen with standard interferons and there were no 
new side effects that could be attributable to peginterferon a-2b. Overall, the incidence and severity of 
adverse events were comparable between the treatment groups. Co=on side effects included flu-like 
symptoms, headache, fatigue and local reaction at the injection site (figure 4A). There were 32 serious 
adverse events (12% of patients), of which 17 were probably related to therapy and all were reversible. 
The adverse events were: hepatitis flare (4), depression (3), severe neutropenia (3), psychosis (1), 
seizures (1), pancreatitis (1), anxiety (1), dizziness (1), diarrhea (1) and syncope (1). All serious 
adverse events were reversible after treatment was stopped. At the end of treatment 91% of patients 
remained on treatment and 69% of patients remained on full dose treatment (figure 4B). There were no 
significant differences in dose reductions between the two treatment groups. 
Discussion 
The current standard initial therapy for patients with chronic HBV infection is with interferon-a or 
lamivudine (22,23). The introduction ofpeginterferons, with their improved pharmacokinetic profiles, 
have led to higher response rates in the treatment of chronic hepatitis C (24,25) and a preliminary 
study suggested improvements in the response rates in HBeAg positive CHB patients (16). In this 
large, randomized study, sustained response (HBeAg loss) in HBeAg-positive CHB patients treated 
with peginterferon a-2b monotherapy was 36%. Treatment with peginterferon a-2b and lamivudine 
combination therapy was superior to peginterferon a-2b monotherapy at end of treatment, but not at 
end offollow up. 
Two earlier, randomized controlled trials comparing combination and monotherapy in HBeAg-positive 
HBV patients include a shorter duration of lamivudine therapy in the group that received combination 
therapy than those who received monotherapy (3,18). This and the timing of primary efficacy endpoint 
(post-treatment for combination therapy or interferon alone versus on-treatment for larnivudine alone) 
prevented a definitive conclusion of the efficacy of combination therapy being reached. The authors 
concluded that the potential benefit of combining lamivudine with interferon therapy should be 
investigated further with different regimens of combination therapy. 
The study reported here progressed these investigations and helps towards drawing a defmitive 
conclusion on the efficacy of combination versus monotherapy for two major reasons. Firstly, it 
compares equivalent duration of treatment in the monotherapy and combination therapy arms. 
Secondly, the prolonged follow-up period extended further beyond the end of treatment with 
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lamivudine than previous studies, which enabled the extent of relapse to be monitored after 26 weeks 
follow up. 
Our study highlights differences in response to interferon and to nucleoside analogues. Despite 
patients initially responding to lamivudine, the response (HBeAg seroconversion and HBV DNA 
reduction) is unsustained. This agrees with previous reports, which noted HBeAg relapse rates of 49% 
to 54% (11, 26). Lack of durability may be due to the mechanism of action of lamivudine, which 
suppresses viral replication without inducing the HBV-specific immune response necessary for 
sustained viral eradication. 
Prolonged therapy with lamivudine is not an option because it usually leads to drug resistance (22, 27). 
This is a particular problem for hepatitis B patients because many patients develop CHB at a relatively 
young age and it is difficult to treat them for several decades with resistance-prone medication for 
which long-term toxicity is unknown. More recently, a study with the nucleotide analogue adefovir 
dipivoxil suggested that response was achieved with development of phenotypic resistance in less than 
1.6% of the patients (9). Future studies are needed to determine whether this response is sustained 
beyond the end of therapy and whether, with continued therapy, clinically relevant drug resistance 
remains absent. 
The study reported here reveals prospectively, for the first time, the importance of HBV genotype as 
independent predictor of treatment response for CHB using interferon. It corroborates with earlier 
retrospective studies, which indicated that HBV genotypes C and D are more difficult to treat than 
genotypes A and B (28-30). Our study indicates that future intervention studies for CHB may need 
stratification according to genotype. 
The side effects and frequency of adverse events observed with peginterferon a-2b monotherapy 
treatment of CHB were similar to those encountered with standard interferon therapy. The rate of dose 
reductions (31%) and discontinuations (9%) was comparable to that reported with peginterferons in 
patients with chronic hepatitis C (15, 24, 25), and with peginterferon a-2a in CHB (16). 
Conclusions 
Peginterferon a-2b is effective and well tolerated for CHB. Sustained clearance of serum HBeAg and 
reduction of viral load are as high or higher than those that have previously been reported for any other 
therapy in this indication. Combination therapy with peginterferon a-2b and lamivudine is not superior 
to peginterferon a-2b monotherapy and HBV genotype is an important predictor of response to 
treatment. 
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Abstract 
The effect of pegylated interferon or its combination with lamivudine on liver histology of patients 
with chronic hepatitis B (CHB) is unknown. In a double-blinded, randomized, multi-center study we 
assessed histological changes in 110 HBeAg-positive CHB patients treated for 52 weeks with 
Pegylated interferon alpha-2b (PEG-IFN)100J.Lg/week in combination with either lamivudine 100 
mglday or placebo. The dose ofPEG-IFN was decreased to 50 J.Lglweek in all patients after 32 weeks 
of treatment. Liver biopsies were taken before and at the end of treatment. All biopsies were blinded 
and scored according to the Ishak system which includes a necroinflammatory score (0-18) and a 
fibrosis score (0-6). Necroinflammatory score improved (defmed as a decrease of at least 2 points) in 
25 patients (48%) of the PEG-IFNI lamivudine combination therapy group and in 31 patients (53%) of 
the PEG-IFN monotherapy group. The fibrosis score improved (decrease of at least 1 point) in 17 
patients (33%) of the combination therapy group versus 13 patients (22%) of the PEG-IFN 
monotherapy group (p=0.23). Responders (n=42), defmed as serum HBeAg negative at the end of 
therapy, showed a larger decline in necroinflammatory score than non-responders (mean decline 2.3 
and 1.2 points, respectively, p=0.02). Among patients receiving PEG-IFN monotherapy 
necroinflammation improved more frequently in responders (78% of responders vs 43% of non-
responders, p=0.01) and in patients who showed normalization of ALT (76% of patients with normal 
ALT vs 40% of patients with abnormal ALT, p=O.Ol). Fibrosis score in the PEG-IFN monotherapy 
group improved more often in responders (39%) than in non-responders (15%, p=0.04). In the PEG-
IFNI lamivudine combination therapy group we found no significant association between virological 
and biochemical endpoints and histological improvement. 
In conclusion, treatment with PEG-IFN therapy improves liver necroinflammation in HBeAg positive 
CHB patients, particularly in responders to therapy. PEG-IFN also improves fibrosis in responders. 
Addition oflamivudine to PEG-IFN did not further improve the histological outcome. 
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Introduction 
The aim of treatment of chronic hepatitis B (CHB) is to prevent progression of liver disease to 
cirrhosis, liver failure and hepatocellular carcinoma. Larnivudine, which strongly suppresses HBV 
replication, has been shown to improve liver inflammation and slow the progression of fibrosis (1-3). 
Histological improvement (decrease of at least two points in total or necroinflammatory Knodell HAI 
score) was found in 49-67% of patients after one year oflarnivudine treatment Interferon therapy for 
16 weeks has also been shown to improve liver histology (3-5). Long-term follow-up studies in 
Caucasian patients treated with interferon showed that the risk of HBV -related complications is 
reduced and survival is better in patients who lose hepatitis B e-antigen (HBeAg) (6, 7). In this study 
we investigated the effect of pegylated interferon alpha-2b (PEG-IFN) therapy alone and in 
combination with lamivudine on liver inflammation and fibrosis. Furthermore, we investigated 
whether virological and biochemical treatment endpoints were associated with improvement of liver 
histology. 
Patients and methods 
Patients 
A total of 266 patients were included in an international randomized double-blinded study (HBV 99-
01 study) reported previously (8). Eligible patients included men and women over 18 years of age with 
chronic hepatitis B, documented by liver biopsy and HBsAg positivity for over six months, and 
detectable serum HBV DNA levels. All patients were HBeAg positive and had AL T levels of at least 2 
times the upper limit of normal on two occasions within eight weeks before randomization. Patients 
were excluded if they had decompensated liver disease (prothrombin time prolonged by ~ 3 seconds, 
serum albumin below 35 g/1, ascites, encephalopathy or a history of variceal bleeding) or any other 
cause of liver disease. Also patients who were coinfected with hepatitis C, hepatitis D or Human 
Immunodeficiency Virus and patients with other significant comorbidity were excluded. 
Study design 
Treatment 
Patients received PEG-IFN 100 J-Lg once weekly and were randomized to receive either lamivudine 100 
mg once daily or placebo. The dose of PEG-IFN was reduced to 50 J-Lg once weekly after 32 weeks of 
therapy. Patients were treated for 52 weeks and then followed for an additional 24 weeks. During 
treatment and follow-up patients were evaluated every 4 weeks through routine physical examinations 
and laboratory assessments. Because liver histology was assessed at the end of therapy, all other 
treatment endpoints (virological, serological and biochemical) were also de:fmed at the end of therapy. 
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Response was defmed as HBeAg negativity at the end of therapy. Relapse was defined as 
reappearance ofHBeAg during follow-up. 
Histology 
Liver biopsies were taken in all eligible patients before the start of therapy. If a recent biopsy (taken 
less than 1 year prior to the start of therapy) was available, no new biopsy was required. A second liver 
biopsy at the end of therapy was optional. All biopsies were blinded and scored by one experienced 
liver pathologist (P .Z.) according to the Ishak system which includes a necroinflarnmatory score (0-18) 
and a fibrosis score (0-6). The Inflammatory score was defined as "improved" if there was a decrease 
of::=::2 points, as "worse" if it increased by :::::2 points. For the fibrosis score improvement was defined as 
a decrease of ::=:::1 point, and worsening as an increase of ::=:::1 point. Overall sample length and the 
number of portal tracts were recorded. Biopsy samples were considered adequate for evaluation if they 
were at least 0.5 em long, contained at least four evaluable portal tracts and were not so fragmented as 
to preclude recognition of acinal architecture. 
Statistical analysis 
Comparisons between groups were made using the chi-square test for categorical variables, and the 
Mann-Whitney test for continuous variables. We used logistic regression for multivariate analysis. The 
following baseline variables were evaluated as prognostic factors for improvement of 
necroinflammation and fibrosis, or with worsening of fibrosis: Sex, race, age, body mass index, 
transmission route, genotype of HBV, ALT, log HBV DNA, previous therapy with lamivudine or 
interferon. Also a separate multivariate analysis was performed to evaluate which treatment endpoints 
were associated with improvement of necroinflarnmation and fibrosis, or with worsening of fibrosis. 
The following treatment endpoints were considered in the model: ALT normalization, HBV DNA 
below 20000 copies/ml, HBV DNA PCR negativity, HBeAg loss and HBeAg seroconversion. 
Results 
Study population 
The 266 patients analyzed in the original international study were eligible for the present histological 
study. Patients were encouraged to undergo a second biopsy at the end of therapy, but this biopsy was 
optional. We obtained paired biopsies from 151 patients (Figure 1). Sixteen biopsies were considered 
not evaluable, because they were too small (<0.5 em). Of the remaining biopsies, 29 biopsies were not 
evaluable because they contained not enough portal tracts (n=12), were too fragmented (n=14) or for 
technical reasons (n=3). These 45 unevaluable biopsies, taken either pre-or post-treatment, came from 
41 patients. Thus, 110 patients with evaluable biopsy pairs were included in the present study. There 
were no significant differences in baseline characteristics between patients for whom histological 
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assessment was feasible or not, therefore the population in the histological study was representative of 
the original study population. Baseline characteristics were comparable for both treatment groups 
(Table 1). 
Table I Baseline characteristics 
PEG-IFNI lanrivudine PEG-IFNI placebo 
(n= 52) (n=58) 
Age* 34±12 33±12 
Sex M1F (%) 38/14 (73%/ 27%) 47/11 (81 %/ 19%) 
Weight (kg)* 74±16 72±13 
Race(%) 
Caucasian 37 (71 %) 43 (74%) 
Asian 10 (19%) 12 (21 %) 
Other/ Mixed 5 (10%) 3 (5%) 
Geographical distribution (%) 
Europe 42 (81%) 49 (85%) 
Asia 5 (9.5%) 6 (10%) 
North America 5 (9.5%) 3 (5%) 
Transmission (%) 
Vertical 13 (25%) 16 (28%) 
Sexual/ parenteral 14 (27%) 13 (22%) 
Unknown 25 (48%) 29 (50%) 
ALT x ULN (U/1)* 4.7±3.3 4.1±3.0 
Log HBVDNA (copies/ ml) 9.1±0.9 9.1±0.8 
Genotype (%) 
A 11 (21%) 16 (28%) 
B 5 (10%) 3 (5%) 
c 8 (15%) 10 (17%) 
D 25 (48%) 27 (47%) 
Previous IFN therapy(%) 10 (19%) 12 (21%) 
Previous lanrivudine therapy(%) 3 (6%) 6 (10%) 
Liver Histology 
Necroinflarnmatory score* 5.4±2.0 5.6±2.2 
Fibrosis score* 2.6±1.5 2.3±1.6 
Cirrhosis (%) 6 (12%) 7 (12%) 
*mean±SD 
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Figure 1 patient population 
Effect of PEG-IFN and PEG-IFN/lamivudine combination therapy on liver histology 
Necroinflammatory score 
The mean necroinflammatory score at baseline was 5.2 (range l-10). Scores were not different 
between treatment groups. Overall, the mean necroinflammatory score improved by 1.6 points 
(p<O.OOl). In both treatment groups we found a significant improvement in necroinflammatory score 
(p<O.OOl), which was not different between the two groups (Table 2). The necroinflammatory score 
improved in 51% of the patients (decrease 22 points), and only 10% showed worsening (increase of22 
points) of necroinflammation. The proportion of patients in each treatment group showing changes in 
liver histology is shown in figure 2. Inflammation improved in 48 % of patients in the PEG-
IFN/lamivudine combination therapy group and in 53% of patients in the PEG-IFN monotherapy 
group (p=0.57). 
Fibrosis score 
At baseline, the mean fibrosis score was 2.4 (range 0-6). Overall the mean fibrosis score increased by 
0.3 points (p=0.03). The fibrosis score improved in 27% of the patients (decrease 21 point). The mean 
fibrosis score increased by 0.2 points in the combination therapy group, and by 0.4 points in the PEG-
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IFN monotherapy group (p=0.59) (Table 2). Improvement of fibrosis was found in 33% of patients in 
the combination therapy group and in 22% of patients in the PEG-IFN monotherapy group (p=0.23). 
Necroinflammatory score 
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Figure 2 Histological response in patients receiving PEG-IFN-lamivudine combination therapy 
and PEG-IFN monotherapy 
Table 2 Histological changes in patients receiving PEG-IFNI lamivudine combination therapy or 
PEG-IFN alone 
PEG-IFNI lamivudine PEG-IFNI placebo 
(n=52) (n=58) 
Necroinflammatory score 
Pretreatment* 5.4± 2.0 5.6±2.2 
(2-9) (1-10) 
Posttreatment* 3.7± 2.0 4.1 ± 1.8 
(l-8) (1-9) 
p (pre- vs posttreatment) <0.001 <0.001 
change* -1.7 -±2.6 -1.5 ± 2.3 
(-71+3) (-71+4) 
Fibrosis score 
Pretreatment* 2.6 ± 1.5 2.3 ± 1.6 
(0-6) (0-6) 
Posttreatment* 2.8 ± 1.8 2.7 ± 1.6 
(0-6) (0-6) 
p (pre- vs posttreatment) 0.23 0.07 
change* 0.2 ± 1.4 0.4 ± 1.5 
(-3/+3) (-2/+5) 
*mean± SD (range) 
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Baseline factors associated with histological improvement 
Multivariate analysis showed that two baseline factors were associated with improvement of 
necroinflammatory scores: low HBV DNA levels (p=0.002), and low body mass index (0.02). Both 
factors were also associated with stable or improved fibrosis stage. The effect of HBV genotype on 
histological response is shown in figure 3. Patients with genotype A showed a significantly larger 
decrease in necroinflammatory scores, compared to genotype D (mean decrease 2.4 vs. 1.1, p=0.02). 
Improvement of necroinflammation was found in 67% of patients with genotype A, 63% of patients 
with genotype B, 50% of patients with genotype C and 42% of patients with genotype D (p=0.04 
genotype A vs D). The difference in histologcal improvement between patients with genotype A and D 
can only partly be explained by a higher (serological) response rate of genotype A. When we analyzed 
responders separately, patients with genotype A showed a mean decrease in necroinflammatory score 
of 3.3, whereas this was only 1.8 for patients with genotype D (p=0.08). Changes in fibrosis score 
were not different between genotypes. 
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Figure 3 Changes in mean necrointlammatory and fibrosis scores within the different genotypes 
Relation of liver histology with virological and biochemical response at the end of therapy 
Loss ofHBeAg 
Loss ofHBeAg (response) was achieved in 24 patients (47%) in the combination therapy group and in 
18 patients (33%) in the PEG-IFN monotherapy group. The mean necroinflammatory and fibrosis 
scores at baseline were higher among patients who showed HBeAg loss (Table 3). Both responders 
and non-responders showed a significant decline in necroinflammatory scores. However, this decline 
was larger in patients who lost HBeAg (mean decline 2.3 vs 1.2 points, p=0.02). Necroinflammation 
improved in 62% (26/42) of responders, but only in 44% (30/68) of non-responders (p=0.07). 
Improvement of fibrosis score was found in 31% (13/42) of responders and 25% (17 /68) of non-
responders (p=.s.). HBeAg loss was significantly associated with improvement ofnecroinflammation 
(78% of responders vs. 43% of non-responders, p=0.01) and reduction of fibrosis (39% of responders 
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vs. 15% of non-responders, p=0.04) in the PEG-IFN monotherapy group, but not in the combination 
therapy group (Table 4). 
Table 3 Histological changes in patients showing HBeAg loss (responders) and patients who 
remained HBeAgpositive at the end of therapy (non-responders) 
N ecroinflanunatory score 
pretreatment 
posttreatment 
p (pre- vs posttreatment) 
change 
Fibrosis score 
pretreatment 
posttreatment 
p (pre- vs posttreatment) 
change 
Responders 
(n=42) 
6.0±2.0t 
(2-9) 
3.7 ± 1.6 
(1-8) 
<0.001 
-2.3 ± 2.4t 
(-7/+3) 
2.8 ± 1.4* 
(0-6) 
3.2 ± 1.9** 
(0-6) 
0.18 
0.4 ± 1.4 
(-2/+3) 
t p=0.07 responders vs. non-responders 
t p=0.02 responders vs. non-responders 
* p=0.02 responders vs. non-responders 
** p=0.07 responders vs. non-responders 
Loss ofHBV DNA 
Non-responders 
(n=68) 
5.2 ± 2.1 t 
(I-I 0) 
4.0 ± 2.1 
(1-9) 
<0.001 
-1.2 ± 2.4t 
(-7/+4) 
2.2 ± 1.6* 
(0-6) 
2.5 ± 1.6 ** 
(0-6) 
0.07 
0.3 ± 1.5 
(-3/+5) 
Among patients that had lost HBV DNA at the end of treatment (PCR negative, detection limit 373 
copies/ml), necroinflammation improved in 64% (16/25), as compared to 47% (40/85) for patients who 
remained PCR positive (p=0.14). In the combination therapy group the proportion of patients that 
showed improvement in necroinflammatory scores was higher in patients that lost HBV DNA than in 
patients that remained PCR positive (62% vs 39 %respectively). In the PEG-IFN monotherapy group 
only 4 of the 58 patients lost HBV DNA. (Table 4). We found no significant association between loss 
ofHBV DNA and fibrosis scores. 
ALT normalization 
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At the end of therapy ALT levels had normalized in 30 patients (58%) in the combination therapy 
group and in 21 patients (36%) in the PEG-IFN monotherapy group. Among patients with normal ALT 
levels at the end of therapy 63% showed improved necroinflammatory scores, compared to 41% of 
patients with persistently abnormal ALT levels (p=0.02). Among patients receiving PEG-IFN 
monotherapy, the necroinflannatory score improved in 76% of patients who normalized ALT, 
compared to 41% of patients who did not (p=0.009) (Table 4). In the PEG-IFN monotherapy group 
progression of fibrosis occurred more often in patients with persistently elevated ALT levels than in 
patients whose ALT levels normalized (49% vs. 19% respectively, p=0.08). We found no significant 
association between ALT normalization and histological changes (necroinflannation or fibrosis) in 
the combination therapy group. 
Table 4 Relation of virological and biochemical endpoints at the end of therapy and histological 
improvement 
Improvement of infla=ation Improvement of fibrosis 
Endpoint PEG-IFNI PEG-IFNI PEG-IFNI PEG-IFNI 
lamivudine placebo lamivudine placebo 
HBeAgloss 
Yes 12124 (50%) 14118 (78%) 6124 (25%) 7118 (39%) 
No 13128 (46%) 17140 (43%) 11128 (39%) 6140 (15%) 
p* 0.80 0.01 0.27 0.04 
HBV DNA loss (PCR 
negative) 
13121 (62%) 314 (75%) 6121 (21%) 214 (50%) 
Yes 
No 
12131 (39%) 28154 (52%) 11131 (36%) 11/54 (20%) 
0.10 0.37 0.60 0.17 
p* 
AL T normalization 
Yes 16130 (53%) 16121 (76%) 11/30 (37%) 6121 (29%) 
No 9122 (41 %) 15137 (40%) 6122 (27%) 7137 (19%) 
p* 0.38 0.01 0.48 0.40 
* p-value represents difference between patients who do and do not reach the endpoint 
Multivariate analysis oftreament endpoints 
Overall, AL T normalization was the only variable independently associated with improved 
necroinflammation (relative risk (RR) 2.5, p=0.02). In the PEG-IFN monotherapy group two factors 
were independently associated with improved necroinflannatory scores: HBeAg loss (RR 3.7, 
p=0.04) and ALT normalization (RR 3.8, p=0.03). In this group, HBeAg loss was also associated with 
improved fibrosis (RR 3.6, p=0.05) and ALT normalization with a decreased risk of worsening of 
46 
Liver histology and PEG-IFN therapy 
fibrosis (RR 0.25, p=0.03). In the combination therapy group we found no significant association 
between treatment endpoints and histological response. 
Effect oflamivudine resistance on liver histology 
Four patients in the combination therapy group developed lamivudine resistant HBV variants (YMDD 
mutants) during therapy. An additional patient had previously been treated with lamivudine and 
harbored a YMDD mutant from the start of therapy. Two of these 5 patients responded to therapy 
(HBeAg loss). Among the 5 patients with YMDD mutants, 3 showed improvement in 
necroinflammatory score, and 2 showed improvement in fibrosis score. None of the patients showed 
worsening ofnecroinflammation or fibrosis. 
Relation of liver histology with relapse 
Relapse (defined as recurrence of HBeAg during post-treatment follow-up) occurred in 9 of the 24 
(38%) responders in the combination therapy group, but only in 2 of the 18 responders in the PEG-IFN 
monotherapy group (ll %) (p=0.05). Among sustained responders 71% had improved 
necroinflammatory score at the end of therapy, compared to 36% of patients who relapsed (p=0.04) 
(figure 4). There were no significant differences in improvement or worsening of fibrosis between 
sustained responders and patients who exhibited a relapse after treatment discontinuation. 
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Figure 4 Histological response in patients with a sustained virological response, relapsers and non-
responders 
Discussion 
This report is the first to describe the histological response to a pegylated interferon in CHB patients. 
Recently, PEG-IFN has shown to be effective in CHB patients, and here we report the histological 
results in the patient group described earlier (8). We found a significant reduction in 
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necroinflammatory activity, and an improved necroinfla=atory score (reduction of at least 2 points) 
in 51% of patients. In addition, 27% of the patients showed reduction of fibrosis. We did not tmd a 
significant difference in histological outcome between patients treated with PEG-IFN alone or PEG-
IFN in combination with lamivudine. 
Several studies have shown that liver histology improves in CHB patients who respond to standard 
IFN therapy (4, 5, 9-11). Perrillo et al. found improved HAI scores in responders and reported 
improvement in liver histology (ranked assessment) in 18 of 30 (60%) patients who responded to 
standard IFN compared to 8 of24 (33%) untreated controls (4). Previously, we also found improved 
HAI scores in responders to standard IFN (5). In the current study with PEG-IFN monotherapy 78% of 
responders showed improved necroinflammatory score and 39% of responders showed reduction of 
fibrosis. 
Histological improvement was significantly associated with HBeAg loss and ALT normalization at the 
end of PEG-IFN therapy. We could not f"md an additional benefit of combination therapy on liver 
necroinfla=ation, despite the greater proportion of patients showing improvement in the virological 
and biochemical markers of the disease at the end of treatment. This might be explained by a larger 
proportion of patients showing a post-treatment relapse in the larnivudine group. Most of these patients 
showed no improvement in necroinfla=ation, which suggests that an adequate immune response, 
rather than virus suppression alone may be required to achieve histological improvement and sustained 
virological remission. 
Prolonged treatment with lamivudine leads to a sustained improvement of necroinfla=ation and has 
been shown to substantially improve fibrosis and even reverse cirrhosis in the majority of patients ( 12, 
13). However the efficacy of larnivudine therapy is limited by the increasing incidence of YMDD 
mutants, which rises to 70-71% after 4 years oflarnivudine treatment (14, 15). In this study we also 
demonstrated that improvement in fibrosis occurred more often in the PEG-IFN/lamivudine 
combination therapy group. In the PEG-IFN monotherapy group improvement of fibrosis strongly 
depended on response, while in the combination therapy group improved fibrosis scores were found in 
37% of non-responders. This might indeed be due to the effect of lamivudine (1-3). Whether this 
beneficial effect of combination therapy is durable after stopping of treatment is still uncertain and 
should be investigated further in future studies. 
We conclude that PEG-IFN therapy improves liver necroinflammation in CHB patients, particularly in 
responders to therapy. Fibrosis improved significantly more often in responders to PEG-IFN. Adding 
larnivudine did not further improve the histological outcome . 
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Abstract 
Treatment of chronic hepatitis B is still only effective in a minority of patients. Attempts are being 
made to improve the efficacy of interferon alpha (IFN) therapy by using pegylated interferons and 
combining its immunomodulatory effect with the potent virussuppressive effect of nucleoside 
analogues. To evaluate viral decline during therapy with pegylated interferon alpha-2b (PEG-IFN) and 
establish if combination therapy with lamivudine has an additive effect, we analyzed viral decline in 
266 HBeAg positive chronic hepatitis B patients treated with PEG-IFN monotherapy or PEG-IFNI 
larnivudine combination therapy. Serum levels of HBV-DNA were measured monthly. Response 
(HBeAg negativity at the end of follow-up) was achieved in 35% of patients (46/130) in the 
combination therapy group and in 36% of patients (49/136) in the PEG-IFN monotherapy group. 
Throughout the study period, we found a significantly faster HBV DNA decline in the combination 
therapy group, compared to the monotherapy group. In the combination therapy group a HBV DNA 
level below 107 geq!ml after 4 weeks of therapy predicted response (sensitivity 95%, specificity 65%, 
positive predictive value 45%, negative predictive value 93%). In the PEG-IFN monotherapy group 
the decline ofHBV DNA was less predictable. In this group more complex HBV DNA decay patterns 
were found. A HBV DNA level below 109 geq/ml after 20 weeks of therapy predicted response in this 
group (sensitivity 94%, specificity 71%, positive predictive value 45%, negative predictive value 
88%). 
We conclude that combination therapy with PEG-IFN and larnivudine is more effective in suppressing 
HBV replication than PEG-IFN alone. This did not result in enhanced sustained response rates. Only 
for patients treated with combination therapy initial decline of HBV DNA was indicative of response. 
For patients treated with PEG-IFN alone response was associated with a delayed HBV DNA decline, 
probably due to the necessary enhanced immune reactivity. In both groups HBV DNA levels during 
therapy could be used to predict response. 
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Introduction 
Treatment of HBeAg-positive chronic hepatitis B is still only effective in a minority of patients. 
Interferon alpha (IFN) has been shown to induce HBeAg seroconversion in one third of patients (1), 
but has considerable side effects. Lamivudine strongly suppresses viral replication and induces 
HBeAg-seroconversion in 16-18% of patients (2-5). However the response to lamivudine is not 
durable after discontinuation of therapy ( 6) and prolonged therapy leads to the emergence of YMDD 
mutant strains in an increasing proportion of patients (7, 8). The response rate to both lamivudine and 
IFN monotherapy is dependent of baseline ALT levels (9, 10). The limited efficacy of standard therapy 
makes new approaches necessary. The efficacy of IFN therapy may be improved by using pegylated 
interferons, which have been shown to produce higher response rates in patients with chronic hepatitis 
C (11-15), and possibly in chronic hepatitis B (16). Combining the virussuppressive and 
immunomodulatory effects of lamivudine and IFN may be more effective than monotherapy with 
either drug (2, 17), particularly in patients with moderately elevated ALT levels (2). To evaluate 
whether viral decline during therapy predicts sustained response (HBeAg loss 6 months posttreatment) 
we analyzed viral decline in HBeAg-positive chronic hepatitis B patients treated with pegylated 
interferon alpha-2b (PEG-IFN) alone or in combination with lamivudine. 
Patients and methods 
Patients 
A total of 266 patients were included in an international multicenter randomized double-blinded study 
reported previously(l8). Eligible patients were men and women over 18 years of age with chronic 
hepatitis B, documented by liver biopsy and HBsAg positivity for over six months, and positive serum 
HBV DNA levels. All patients were HBeAg-positive and had AL T levels of at least 2 times the upper 
limit of normal on two occasions within eight weeks before randomization. Patients were excluded if 
they had decompensated liver disease (prothrombin time prolonged by 2': 3 seconds, serum albumin 
below 35 g/1, ascites, encephalopathy or a history of variceal bleeding) or any other cause of liver 
disease. Also patients who were coinfected with hepatitis C, hepatitis D or Human Immunodeficiency 
Virus and patients with other significant comorbidity were excluded. 
Study design 
Patients received PEG-IFN 100 11g once weekly and were randomized to receive either lamivudine 100 
mg once daily or placebo. The dose ofPEG-IFN was reduced to 50 11g once weekly after 32 weeks of 
therapy. Patients were treated for 52 weeks and followed for 6 months posttreatment. Serum samples 
for HBV DNA measurement were taken at the start of therapy (day 0), and thereafter monthly until the 
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end of follow-up. HBV DNA levels were measured using an in-house developed TaqMan real-time 
PCR test. (dynamic range 4x102-10 10 copies/ml) (19). The Eurohep HBV DNA standard was used for 
validation of HBV DNA levels (20). HBeAg was measured using a commercially available 
immunoassay (Abbott Laboratories, Abbott Park, Il). Response was defmed as HBeAg negativity at 
the end offollow-up. 
Statistical analysis 
Comparisons between groups were done using the chi-square test for categorical variables, and the 
Mann-Whitney test for continuous variables. To investigate whether response could be predicted at an 
early timepoint during therapy, HBV DNA levels and HBV DNA decline from baseline to each 
timepoint from week 4 to 32 were assessed as possible predictors of response. For each test areas 
under the receiver operating characteristic (ROC) curves were calculated, and compared using the 
method of DeLong et aL(21). Also for each timepoint different levels (in half-log steps) ofHBV DNA 
and decline from baseline were assessed to determine which cut-off level best excluded patients who 
failed to respond. 
Results 
Patient characteristics 
Patient characteristics are shown in table 1. Of the 266 patients, 205 were male (77%) and 199 were of 
Caucasian origin (75%). The PEG-IFN monotherapy and PEG-IFNI lamivudine combination therapy 
groups were comparable with respect to all baseline parameters. Previously 55 patients (21 %) had 
been treated with standard IFN, and 33 patients (12%) with lamivudine. None of the patients had 
received any antiviral therapy within 6 months of entering the study. 
Viral decline with PEG-IFN alone and PEG-IFN/iamivudine combination therapy 
The decline ofHBV DNA during therapy is shown in figure 1. The combination therapy group showed 
a biphasic decline, whereas the decline in the PEG-IFN monotherapy group showed a less consistent 
pattern. In the PEG-IFN monotherapy group 57 patients (43%) showed a decline of at least 0.5 log 
during the first month of therapy. Another 36 patients (27%) showed no initial decline, but a delayed 
decline of at least 2 log from baseline during week 4-32 of therapy (n=17), week 32-52 of therapy 
(n=S) or during follow-up (n=ll). The monthly HBV DNA decline was significantly less in the 
monotherapy group than in the combination therapy group during the first 24 weeks (p<O.Ol) and 
again during weeks 24-28 of therapy (p=O.Ol). Patients in the combination therapy group had 
significantly lower mean HBV DNA levels at all timepoints during therapy. After de end of therapy, 
however, HBV DNA levels for both groups became comparable 
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Table 1 Baseline characteristics 
PEG-IFNI lamivudine PEG-IFNI placebo 
Age* 
Sex MIF (%) 
Weight (kg)* 
Race(%) 
Caucasian 
Asian 
Other/ Mixed 
Transmission (%) 
Vertical 
Sexual/ parenteral 
Unknown 
ALT x ULN (U/1)* 
Log HBVDNA (copies/ ml)* 
Genotype(%) 
A 
B 
c 
D 
Cirrhosis(%) 
Previous IFN therapy (%) 
Previous lamivudine therapy (%) 
*mean±SD 
(n= 130) 
34±12 
98/32 (75/ 25) 
74±16 
98 (73) 
32 (18.5) 
11 (8.5) 
29 (22) 
32 (25) 
69 (53) 
4.4±3.9 
9.1±1.0 
43 (33) 
11 (9) 
18 (14) 
52 (40) 
13/107 (12) 
27 (21) 
17 (13) 
Relation of viral decline and response 
(n=136) 
36±14 
107/29 (79/ 21) 
72±13 
101 (74) 
29 (21) 
6 (4) 
31 (23) 
33 (24) 
72 (53) 
4.3±3.1 
9.0±1.0 
47 (35) 
12 (9) 
21 (15) 
51 (38) 
11/106 (10) 
28 (21) 
16 (12) 
Response (HBeAg negativity at the end of follow-up) was achieved in 35% of the PEG-
IFN/lamivudine combination therapy group and 36% of the PEG-IFN monotherapy group (p=n.s.). 
The viral decline for responders and non-responders treated with PEG-IFN alone or the combination is 
illustrated in figure 2. For the combination treatment group both responders and non-responders 
showed a significant drop in HBV DNA whereas in the PEG-IFN monotherapy group HBV DNA was 
minimal in non-responders. In the combination therapy group most patients showed a biphasic decline. 
During the first month there was a rapid decline in HBV DNA, which was significantly faster in 
responders (3.2 log) thanin non-responders (2.8 log, p=O.Ol). Thereafter we found a slower decline in 
viral load, which was not different between responders and non-responders. In the PEG-IFN 
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monotherapy group 57 patients (43%) showed a decline ofHBV during the first month of therapy. We 
defined HBV DNA decline as a decrease of at least 0.5 log during the fust month, regarding the 
variability of the test. This immediate decline resulted in response in 51% (Table 2). Among patients 
who showed no such decline during the first month of therapy we found a different decline pattern 
with a sudden fast HBV DNA decline after a variable delay. This delayed HBV DNA decline, defmed 
as a drop ofHBV DNA to at least 2 logs below the baseline level after the first month of therapy, was 
found in 25 patients (19%). Among the 17 patients who showed this delayed HBV decline within 
weeks 4-32 of therapy, 76% responded. 
Figure 1 HBV DNA levels during therapy: PEG-IFN monotherapy (dashed line) versus 
combination therapy ofPEG-IFN and lamivudine (solid line). 
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Table 2 Association of pattern of viral decline during therapy with response in the PEG-IFN 
monothera 
Pattern 
% of patients 
responding 
Immediate decline (n=57)* 51% 
Delayed decline (n=25)** 
Week4-32 (n=l7) 
Week 32-52 (n=S) 
No decline (n=52) 
76% 
25% 
10% 
* ;,: 0.5 log during first month of therapy 
% of responders 
showing pattern 
59% 
27% 
4% 
10% 
** ;,: 2 log from baseline after first month of therapy 
56 
% of non-responders 
showing pattern 
33% 
5% 
7% 
55% 
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Figure 2 HBV DNA levels for responders (defined as HBeAg negative at week 78) and non-
responders to PEG-IFN monotherapy (A) and PEG-IFN/lamivudine combination therapy (B) 
Prediction of response 
PEG-IFN and lamivudine. When we analyzed HBV DNA levels and decline at the different timepoints 
for discrimination between responders and non-responders, the largest area under the ROC curve was 
found for viral load at week 12. To find the earliest possible moment for prediction we compared this 
with earlier timepoints. We found that the area under the ROC curve was comparable for testing at 
week week 4 (0.69) and week 12 (0.75, p=O.l7). The ROC curves showing the relation between viral 
load at weeks 4 and 12 and response are shown in figure 3. The association between response and 
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HBV DNA levels at week 4 is shown in table 3. Response could best be predicted by a log HBV DNA 
level below 7.0 at week 4, which included 95% of responders, and excluded 35% of non-responders. 
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Figure 3 ROC curve for prediction of response in the PEG-IFN!lamivudine therapy group by 
testing HBV DNA level at weeks 4 and 12 of therapy. The area under the curve was not 
significantly different between the two tests. 
Table 3 Prediction of response in the combination therapy group at week 4 of therapy 
LogHBVDNA % of patients Positive Negative %of %of non-
level at week 4 of reaching level predictive predictive responders responders 
therapy value value included excluded 
<7.5 85% 40% 89% 95% 21% 
<7 76% 45% 93% 95% 35% 
< 6.5 66% 48% 88% 88% 47% 
PEG-IFN and placebo. In the group of patients receiving PEG-IFN monotherapy, analysis of response 
showed the largest area under the ROC curve for HBV DNA levels at week 32 of therapy. Here we 
also compared with earlier timepoints. To be able to make a prediction as early as possible, we 
selected week 20, which was the earliest timepoint with area under the ROC curve (0.80) was not 
significantly different from the area under the ROC curve at week 32 of therapy (0.83, p=0.20). The 
ROC curves showing the relation between response and viral load at weeks 20 and 32 are shown in 
figure 4. Response could best be predicted by a log HBV DNA level below 9.0 at week 20 of therapy, 
which included 94% of responders and excluded 29% of the non-responders (Table 4). 
58 
Viral decline during PEG-IFN therapy 
-o 
co 
E 
c 
co 
:2 
~ 
co 
-o 
c 
0 
c. 
UJ 
~ 
0 
c 
0 
'E 
0 
c. 
.75 
.50 
.25 
e 
c.. 0.001111'----~---~---~-------< 
0.00 .25 .50 .75 1.00 
Proportion of non-responders missed 
week32 
week20 
Figure 4 ROC curve for prediction of response in the PEGIIFN placebo group by testing HBV 
DNA level at weeks 20 and 32 of therapy. The area under the curve was not significantly 
different between the two tests. 
Table 4 Prediction of response in the PEG-IFN mono therapy group at week 20 of therapy 
LogHBVDNA % of patients Positive Negative %of %ofnon-
level at week 20 of reaching level predictive predictive responders responders 
therapy value value included excluded 
<9.5 86% 43% 94% 98% 21% 
<9 80% 45% 88% 94% 29% 
< 8.5 62% 51% 83% 83% 51% 
Discussion 
Throughout the treatment period, we found a significantly faster decline of HBV DNA in the PEG-
IFNI larnivudine combination therapy group, compared to the PEG-IFN monotherapy group. HBV 
DNA in the combination therapy group showed a biphasic decline, as has previously been described 
with conventional IFN or PEG-IFN in chronic hepatitis C patients (22-26), and in chronic hepatitis B 
patients treated with nucleoside analogues (27-31). In the PEG-IFN monotherapy group there was a 
less consistent pattern of HBV DNA decline. Despite the difference in initial HBV DNA decline, in 
our group of 266 HBeAg positive patients there was no difference in sustained off-treatment HBeAg 
response between PEG-IFN monotherapy and PEG-IFNI larnivudine combination therapy (18). In the 
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combination therapy group both responders and non-responders showed a marked decline of HBV 
DNA during therapy, with a fast relapse in non-responders but not in responders after the end of 
therapy. With PEG-IFN monotherapy only responders showed a HBV DNA decline, which was 
sustained during follow-up. Non-responders in this group showed no or a minimal decline of HBV 
DNA. 
Looking at the individual patients, HBV DNA decline in the PEG-IFN monotherapy group followed a 
variable pattern. In this group 27% of patients initially showed a very slow decline or no change in 
viral load, followed after a variable delay by phases of sudden fast HBV DNA decline during 
treatment. This delayed viral decay probably reflects immune activation induced by PEG-IFN. We 
found that in patients treated with PEG-IFN alone a delayed viral decline during weeks 4-32 was 
associated with response in 76% of the patients. After 20 weeks of therapy a prediction of response 
could be made on the HBV DNA level at that time. A HBV DNA level below 107 geqlml after 20 
weeks predicted response in 45%; If HBV DNA remained above this level the chance of response was 
5%. In the combination therapy group responders had a faster decline of HBV DNA during the first 
month of therapy than non-responders. The HBV DNA level after 4 weeks of therapy could be used to 
predict response in this group. A HBV DNA level below 109 geqlrnl predicted response in 45% of 
patients. IfHBV DNA was above this level the chance of response was 6%. These results might give a 
useful tool to decide whether or not to continue PEG-IFN therapy. It provides the opportunity to 
discontinue therapy in patients who are unlikely to respond, which limits the side effects and burden of 
treatment for these patients and also enhances cost-effectiveness. Also it motivates patients who reach 
the early goal of treatment to continue therapy, knowing they have a good chance of responding. 
Figure 5 shows the proposed stopping rules for both treatment groups. 
We conclude that combination therapy with PEG-IFN and lamivudine is more effective in suppressing 
HBV replication than PEG-IFN alone. This did not result in enhanced rates of sustained HBeAg loss. 
Only for patients treated with combination therapy initial decline of HBV-DNA was indicative of 
response. For patients treated with PEG-IFN alone response was associated with HBV-DNA decline 
after 12 weeks, probably due to enhanced innune reactivity. 
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Figure 5 Algorithm for HBV DNA testing to identify patients with a high chance of response 
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Abstract 
Treatment with interferon-alpha (IFN) has been shown to be effective in one third of HBeAg-positive 
chronic hepatitis B patients, but is clinically associated with relevant adverse events. We studied the 
safety of pegylated interferon alpha-2b (PEG-IFN) in three hundred HBeAg-positive patients with 
compensated liver disease. Patients were treated with PEG-IFN for 52 weeks combined with either 
lamivudine lOOmg/day or placebo. PEG-IFN was administered for lOO).!g once a week for 32 weeks, 
thereafter the dose was reduced to 50 ).!g once a week. Adverse events and their effect on study 
medication were reported at monthly visits in a standardized way. The most frequently reported side 
effects were flu-like-syndrome (68%), headache (40%), fatigue (39%), myalgia (29%) and local 
reaction at the injection site (29%). These symptoms typically occurred within the flrst month of 
therapy and subsided during the course of therapy. 
Neutropenia and thrombocytopenia induced by PEG-IFN increased the risk of infections and bleeding 
complications, but these complications were rare and mild. The frequency of all side effects was not 
different between patients treated with PEG-IFN combined with lamivudine or placebo. In 69 (22%) 
patients the dose ofPEG-IFN was reduced prematurely. Of these dose reductions 36 (52%) were due 
to neutropenia. Therapy was discontinued in 28 (8%) patients. The most frequent reasons for early 
discontinuation were psychiatric side effects (depression, psychosis) and flu-like symptoms. 
Multivariate Cox regression analysis showed that low neutrophil count at baseline and cirrhosis were 
independent predictors of dose reduction or therapy discontinuation. We conclude that in patients with 
chronic hepatitis B and compensated liver disease prolonged PEG-IFN therapy is safe and that 
preexistent cirrhosis and neutropenia are the most important predictors of dose reduction or early 
treatment discontinuation. 
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Introduction 
An estimated 400 million people are chronically infected with hepatitis B virus (HBV). Chronic 
hepatitis B is worldwide the single most common cause of liver cirrhosis and hepatocellular carcinoma 
(HCC). (1). Interferon alpha (IFN) is effective in about one third of patients(2). Reported HBeAg 
seroconversion rates range from 15 to 37 percent (3-5), depending on baseline characteristics such as 
AL T levels and viral load. Response to IFN therapy has been shown to result in sustained clearance of 
HBeAg, HBV DNA and normalisation of aminotransferase levels (6-8). Therapy with IFN is 
associated with considerable side effects. Most frequently reported side effects are flu-like syndrome, 
fatigue, headache and myalgia. Other clinical relevant side effects, such as depression, anorexia and 
insoumia, occur less frequently. Cases of suicide attempts during IFN therapy have been reported (9-
11). To improve response rates and reduce the number of side effects, newer forms of IFN have been 
developed. "Pegylated" forms of IFN (with a polyethylene glycol moiety attached to it) have an 
improved pharmacokinetical profile with a prolonged half-life time (9). Pegylated interferons have 
been reported to be safe and more effective than conventional IFN in patients with chronic hepatitis C 
(12, 13). Until now the safety data of these pegylated forms ofiFN in the treatment of chronic hepatitis 
Bare limited to the study ofCooksley et al.(14), who investigated the safety ofpeginterferon alpha-2a 
in chronic hepatitis B patients. In this study we assessed the safety of pegylated interferon alpha-2b 
(PEG-IFN) alone or in combination with larnivudine in HBeAg-positive chronic hepatitis B. 
Materials and methods 
Patients 
In a randomized multicenter trial reported previously (15), three hundred and seven HBeAg-positive 
CHB patients with compensated liver disease were treated with PEG-IFN in combination with either 
larnivudine or placebo. Inclusion criteria were hepatitis B surface antigen (HBsAg)-positivity for at 
least 6 months, age 2': 16 years, alanine arninotranferase (AL T) at least twice the upper limit of normal 
(ULN) and HBeAg positive on two occasions within 8 weeks prior to randomization. Patients were 
excluded if they had been treated with antiviral medication within 6 months or any investigational drug 
within 30 days of entry to this protocol, were coinfected with hepatitis C, hepatitis D or HIV, had 
alcoholic hepatitis or other causes of liver disease, had pre-existent leukopenia or thrombocytopenia 
(white blood cell count (WBC) ::'0 3,000/mm3, neutrophils ::'0 1,800/mm3, platelets ::'0 100,000/mm3), had 
decompensated liver disease (prothombin time prolonged by 2': 3 sec, serum albumin < 35 gil, ascites, 
encephalopathy, history of variceal bleeding) or had hypo- or hyperthyroidism. Patients were also 
excluded in case of pregnancy, inadequate contraception, any significant medical illness potentially 
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interfering with the study or any contraindication specified for IFN. Ethics committees of the 
participating centers approved of the protocol and all patients provided written informed consent. 
Study design 
In this double-blinded trial, eligible patients were randomized to one of two treatment regimens 
(Figure 1). All patients received PEG-IFN for 52 weeks. Patients were treated with a dose of 100 J.lg 
PEG-IFN once a week until week 32, whereafter the dose was reduced to 50 J.lg once a week. In 
addition, patients received either placebo or 1 00 mg larnivudine orally. 
PEG-IFN 1 00 J.l9 I PEG-IFN 50 J.l9 
Follow-up 
Lamivudine 
PEG-IFN 100 J.l9 l PEG-IFN 50 J.l9 
Placebo 
Follow-up 
t t t t 
0 32 52 78 weeks 
Figure 1 Treatment schedule 
Patients were followed every four weeks during treatment and during the post-treatment follow-up 
period of six months .. At visits routine physical examination was performed and blood samples were 
obtained for hematological and biochemical screening (hemoglobin, white blood cells, neutrophils, 
platelets, ALT and aspartate aminotranferase(AST)). All adverse events were reported by the treating 
physician on standard case record forms and verified by the trial coordinating center. All participating 
investigators were instructed, received a protocol and were monitored every 3 months in order to 
uniform scoring of side-effects. Adverse events were graded according to the WHO reco=endations 
for grading of acute and subacute toxicities (16), and reported as mild, moderate, severe or life-
threatening. The reported adverse events were also judged in their relation to therapy by the treating 
physician and reported as unrelated, possibly related, probably related or related to therapy. Effect on 
study medication was scored as none, dose reduction or treatment discontinuation. Serious adverse 
events (SAE) were defined as events resulting in death, events which are life-threatening, require or 
prolong inpatient hospitalisation, as well as events which result in persistent or significant disability or 
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incapacity, pregnancy, any congenital anomaly, cancer, or drug overdose. Hepatitis flares were 
defined as an increase in serum alanine aminotransferase (ALT) to at least 3 times the baseline leveL 
Guidelines on discontinuation of therapy in case of flares were provided to each investigator before 
start of therapy. The decision to stop therapy in patients with flares and signs of diminished liver 
function was left at the responsibility of the participating doctor who treated the patient. 
Statistical Analysis 
Kaplan-Meier analysis was used to assess time until dose reduction or premature discontinuation of 
therapy. For univariate analysis the following factors were considered: age, gender, race, mode of 
transmission, baseline levels of AST, ALT, bilirubin, neutrophils, platelets and HBV DNA, previous 
therapy with IFN or lamivudine and presence of cirrhosis. To assess which variables independently 
predicted dose reduction or early discontinuation of therapy variables that were significant or 
approximated significance in the univariate analysis (p-value <0.2) were included in a multivariate 
analysis. Cox regression was used for multivariate analysis. Chi-square was used to compare 
frequencies of adverse events. All statistical analyses were performed in SPSS version 10 (SPSS Inc, 
Chicago, Il). 
Results 
Baseline characteristics 
A total of 307 patients were randomized to treatment with PEG-IFN and either lamivudine or placebo. 
The analysis of efficacy, that was reported previosly, was done for 266 patients, and excluded patients 
that never started treatment (n=7), were HBeAg negative at the start of treatment (n=lO), and patients 
from one single center where source data could not be verified (n=24)(15). Because safety data were 
available and could be verified for all patients, the 300 patients that received at least one dose of study 
medication were included in the present safety analysis. The baseline characteristics of these patients 
are shown in table L A total of 228 men (76%) and 72 women were treated with PEG-IFN in 
combination with either lamivudine or placebo. The mean age of the patients was 35 years (range 16-
72). The majority of patients (76%) were Caucasians. For 230 patients pretreatment biopsies were 
available and of sufficient quality to be evaluated. Of these patients 26 patients (11%) had cirrhosis at 
liver biopsy. Among the 300 patients, 71 patients (24%) had been treated with IFN, and 45 (16%) with 
larnivudine prior to entry in this study. 
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Table 1 Patient characteristics at baseline 
Characteristics 
Age (yrs) 
Gender, n (%) 
Male 
Female 
Weight (kg) * 
Race, n(%) 
Caucasian 
Asian/ Other 
Mode of transmission, n (%) 
Vertical 
(Homo )sexual 
Parenteral 
Transfusion associated 
Unknown 
Previous IFN therapy, n (%) 
Previous lamivudine therapy, n (%) 
Histological diagnosis(%) 
Cirrhosis 
No cirrhosis 
ALT(xULN)* 
Platelets (1 09/L) 
Neutrophils 
LogHBVDNA* 
*mean±SD 
Side effects 
(n = 300) 
35 ± 13 
228 (76) 
72 (24) 
73 ± 14 
228 (76) 
72 (24) 
66 (22) 
31 (1 0) 
27 (9) 
8 (3) 
173 (56) 
71 (24) 
45 (16) 
26 (11) 
204 (89) 
4.3 ±3.5 
204±60 
3.4 ± 1.3 
9.0 ± 1.1 
All treated patients reported one or more of the known side effects of IFN. The frequency of all side 
effects was not significantly different between the PEG-IFNI placebo group and the PEG-IFNI 
lamivudine group. Also there was no difference in occurrence of SAE and in need for dose reduction 
or premature treatment discontinuation between the treatment groups. Therefore we combined the data 
of the two groups for all analyses. The most frequently reported adverse events were flu-like-syndrome 
(68%), headache (40%), fatigue (39%), myalgia (29%) and local reaction at the injection site (29%) 
(Table 2). These symptoms typically occurred within the first month of therapy and mostly subsided 
during the course of therapy. Alopecia and psychiatric symptoms (including depression (n = 26) and 
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mood changes or irritability without depression (n = 33)) occurred later in the course of therapy (Fig 
2). During therapy leucopenia(< 3.0 x 109 u/L, grade II), neutropenia(< 1.5 x 109 u/L, grade II) and 
thrombocytopenia (< 75 x 109 u/L, grade II) occurred in 42, 22 and 12 percent of the patients, 
respectively (Table 2). All adverse events were reported less frequently after dose reduction and were 
completely reversible after the end of therapy (Figure 2). 
Table 2 Frequencies of adverse events 
Adverse event 
Flu like Syndrome 
Headache 
Fatigue 
Myalgia 
Local reaction 
Alopecia 
Weight loss ( > 10 %) 
Psychiatric • 
Abdominal pain 
Haematologic events 
Leucopenia(< 3.0 x 109 u/L) 
Neutropenia(< 1.5 x 109 u/L) 
Thrombocytopenia(< 75 x 109 u/L) 
*Includes depression, mood changes, irritability 
Hepatitis flares 
Freq% 
68 
40 
39 
29 
29 
22 
19 
20 
15 
42 
22 
12 
A total of 71 hepatitis flares were reported, occurring during therapy in 31 patients and after the end of 
therapy in 40 patients. Flares occurred in 25% (371148) of patients in the PEG-IFNI lamivudine group 
and in 22% (341152) of patients in the PEG-IFNI placebo group (p=0.5). The frequency of on-
treatment flares and post-treatment flares was not different between groups. Two flares led to 
discontinuation of therapy. None of the hepatitis flares resulted in sustained decompensated liver 
disease or death. 
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A 
Week Week Week 
100J.I.gPEG/wook llli&lllilillll 
50 11-9 PEG/wook ~ 
Follow-up ~ 
Week Weok 
B 
70~----------------------------------------------------. 
60 
- Week0-32 
~ Week32-52 
50 [G¥4tt~'Z't%!f;%ill Week 52-78 
40 
36 
30 26 
19 20 17 
12 
10 
Flu Headache Fatigue Myalgia Alopecia Neutropenia Thrombocytopenia 
Figure 2 Course of frequent adverse events during therapy and follow-up (A) and 
adverse events: Frequency of events in relation to PEG-IFN dose (B). 
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Serious adverse events 
During the study 33 SAE were reported. Of these SAE 17 were judged as probably related to therapy. 
Four patients had a serious hepatitis flare, and three patients developed severe depression. Neutropenia 
(grade III or lV) was reported in three cases. Other SAE that were probably related to therapy were 
syncope, seizures, psychosis, pancreatitis, diarrhea, anxiety and dizziness (resulting in a fall and a head 
wound). In 14 patients the serious adverse event led to early discontinuation of therapy (depression (n 
= 4), flare (n = 2), neutropenia, seizures, pneumonia, psychosis, pancreatitis, severe diarrhoea, allergic 
reaction with hypotension and pregnancy (all n = 1). 
Bacterial infections and bleeding complications 
Bacterial infections occurred in 12 patients (4%). Nine of these 12 patients had neutropenia of at least 
grade II (<1.5 x 109/L) (Table 3). The risk of infection increased with an increasing severity of 
neutropenia. Patients with neutrophil counts below 1.5 x 109 !L had a significantly increased risk of 
infection compared to patients with higher neutrophil counts (13.6% versus 1.3% respectively, 
p<0.001). Infections included urinary tract infection (n = 4), gastro-enteritis (n = 2), tonsillitis (n = 2), 
gingivitis (n = 2), appendicitis (n=l) and pneumonia (n = 1). Overall, three severe bacterial infections 
were reported. In two of these cases (pneumonia and appendicitis) the neutrophil count never dropped 
below 1.5 x 109 !L. The third patient had a salmonella gastro-enteritis while his neutrophil count was 
0.7 x 109 /L. In four cases (pneumonia, appendicitis and gastroenteritis (n=2)) the infection necessitated 
hospital admission. All infections resolved without lasting complications. 
Table 3 Bacterial infections in patients with low neutrophils. 
Neutrophils (UIL) n Bact. Infections (%) 
> 1.5 X 109 234 3 (1.3) 
< 1.5 X 109 66 9 (13.6) 
< 1.0 X 109 24 2 (8.3) 
<0.5xl09 9 1(11.1) 
Reported bacterial infections: urinary tract infection (n = 4), gastro-enteritis (n = 2), tonsillitis (n = 2), 
gingivitis (n = 2), pneumonia (n = 1 ), appendicitis (n= 1) 
The risk of bleeding complications was increased in patients with thrombocytopenia, especially grade 
III(< 50 x 109/L) or N. Reported bleeding complications in these patients were epistaxis (n = 2), GI 
bleeding, subcutaneous bleeding and combined ecchymosis plus epistaxis (Table 4A). Cirrhotic 
patients (n=25) had a significantly higher risk of developing thrombocytopenia than non-cirrhotic 
patients (54% vs 8 %, p <0.001). Three of the cirrhotic patients (developing thrombocytopenia grade 
II and III) had bleeding complications (Table 4B). The reported bleeding complications were not life-
threatening and did not necessitate blood transfusions. 
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Table 4 Bleeding complications in patients with low platelets 
A Bleeding complications according to level of thrombopenia 
Platelets (U/L) n Bleeding complications (%) 
> lQQ X 109 222 6(2.7) 
< 100 X 109 78 5(6.4). 
< 75 X 109 37 3(8.1) 
< 50 X 109 9 2(22.2) 
B Bleeding complications in cirrhotic patients 
Cirrhosis (n = 26) No Cirrhosis (n = 204) 
Platelets (U/L) 
Bleeding complications 
N 
Bleeding complications 
n 
n(%) n (%) 
> 75 X 109 12 0 (0) 188 4 (2) 
< 75 X 109 14 3 (21) 16 0 (0) 
*Reported bleeding complications in patients with platelets < 100 x 109 U/L: epistaxis (n = 2), GI 
bleeding (n = 1), subcutaneous bleeding (n = 1), ecchymosis and epistaxis (n = 1) 
Dose reduction and discontinuation of therapy 
In 69 patients (23%) the dose ofPEG-IFN was reduced prematurely (Table 5). Of the dose reductions 
37 (54%) occurred in the PEG-IFNI lamivudine group and 32 (47%) in the PEG-IFNI placebo group. 
The dose of the blinded drug (lamivudinelplacebo) was not reduced in any of the patients. The main 
reasons for dose reduction were neutropenia (52%), thrombocytopenia (10%), flu-like syndrome 
(10%) and combined haematological abnormalities (8%). In four patients (6%) dose reduction was 
necessary due to psychiatric symptoms and in seven patients due to flu-like-syndrome. Fifty percent of 
the dose reductions occurred within the first ten weeks. Hereafter the number of dose reductions 
decreased. Only two dose reductions were reported after week 32. 
PEG-IFN therapy was discontinued prematurely in 28 patients (9%). In 24 patients the blinded drug 
(lamivudinel placebo) was also discontinued In ten patients therapy discontinuation was due to 
psychiatric side effects. The second clinically important reason for discontinuation was flu-like-
syndrome (n = 3). Other reasons for early discontinuation were acute pancreatitis, flare, 
decompensated liver disease and seizures (Table 5). Discontinuation of therapy was reported more 
frequently before the scheduled dose reduction of PEG-IFN at week 32. In univariate analysis, a low 
neutrophil count ( <3 x 1 09 /L) at baseline and presence of liver cirrhosis were associated with an 
increased risk of dose reduction or discontinuation of therapy (Table 6). Cox regression analysis, 
including all variables with a p-value below 0.2 in the univariate analysis, showed that both low 
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neutrophil count (hazard ratio 1.7, p=0.03) and cirrhosis (hazard ratio 2.5, p=O.OOl) remained the only 
independent predictors of dose reduction or discontinuation of therapy. 
Table 5 Reasons for dose reduction and early discontinuation 
Dose reduction n(%) Early discontinuation n(%) 
Neutropenia 36 (52) Psychiatric 10 (36) 
Thrombocytopenia 7 (10) Flu like syndrome 3 (11) 
Leucopenia 2 (3) Patient lost to follow-up 4 (14) 
Combined hematological 6 (8) Anemia 1 (4) 
Flu like syndrome 7 (10) Neutropenia 1 (4) 
Psychiatric 4 (6) Thrombocytopenia 1 (4) 
Fatigue 2 (3) Flare 1 (4) 
Local reaction 1 (1) Seizures 1 (4) 
Anorexia 1 (1) Acute pancreatitis 1 (4) 
Myalgia 1 (1) Decompensated liver disease 1 (4) 
Other 2 (3) Pneumonia 1 (4) 
Other 3 (11) 
Total 69 Total 28 
Discussion 
The side effects of conventional IFN therapy have been well documented in patients with chronic 
hepatitis Band C (8, 12, 14, 17, 18). The most common side effects include influenza-like symptoms, 
fatigue, gastrointestinal symptoms (nausea, anorexia, weight loss), alopecia and neuropsychiatric 
symptoms (irritability, depression, insomnia). IFN also causes mild bone marrow depression with a 
temporary decrease in neutrophil, leukocyte and platelet counts. These side effects have an impact on 
the quality of life, and can lead to dose reduction or treatment discontinuation. This report is the first 
on safety of PEG-IFN in patients with chronic hepatitis B. All patients reported one or more of the 
known adverse events of standard IFN. The adverse events reported in our patients are largely those 
expected of standard IFN, and no new unexpected events were reported. The frequency of the most 
common adverse events- flu-like-syndrome (66%), headache (39%), fatigue (37%) and myalgia (28%) 
-was comparable to those previously reported in chronic hepatitis B patients treated with standard IFN 
in a dose of 4.5 MU (14) or 10 MU t.i.w.(l7) for 16-32 weeks. Obviously, these comparisons with 
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Table 6 Univariate analysis of association of baseline factors with dose modifications (dose reduction 
or discontinuation of therapy) 
Variable 
Age 
<35 
~35 
Sex 
Male 
Female 
Weight 
<75kg 
~75kg 
Race 
Caucasian 
Asian/ Other 
ALT 
<4xULN 
~4xULN 
LogHBVDNA 
<9 
~9 
Bilirubin 
<ll 
~ll 
Platelets (x 109/L) 
<200 
~200 
Neutrophils (x 109/L) 
<3 
~3 
Cirrhosis 
No 
Yes 
Previous IFN therapy 
Yes 
No 
Previous lamivudine therapy 
Yes 
No 
76 
Risk of dose modifications (%) 
27 
34 
29 
35 
34 
25 
28 
37 
29 
32 
36 
26 
28 
31 
34 
25 
39 
24 
29 
62 
34 
28 
38 
27 
p-value 
0.19 
0.27 
0.11 
0.07 
0.47 
0.06 
0.57 
0.13 
0.003 
0.0005 
0.34 
0.15 
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historical controls must be interpreted with caution, as the treatment duration in our study was longer 
and patient populations and therapy doses differ between studies. 
Pegylated interferons have been reported to be safe and more effective in patients with chronic 
hepatitis C (8, 11, 12, 18, 19). In hepatitis C patients the side effect profile is the same as that of 
standard IFN, with some difference in frequencies between different doses and formulations. 
Hematological abnormalities (especially neutropenia) occur more frequently in chronic hepatitis C 
patients treated with pegylated interferons (PEG-IFN or peginterferon alpha-2a) than with standard 
IFN. The rate of dose reductions (22%) and therapy discontinuations (9%) in our study is comparable 
to the frequencies reported with pegylated interferons in patients with chronic hepatitis C (8, 12, 13, 
20) and with 24 weeks of peginterferon alpha-2a in patients with chronic hepatitis B (14). The 
proportion of patients that is withdrawn from therapy with pegylated interferons is similar to that of 
conventional IFN, but, as compared to standard IFN, the proportion of patients requiring dose 
reductions is higher with PEG-IFN in most hepatitis C studies (8, 11, 12, 18). In chronic hepatitis B 
patients the frequency of dose reduction with peginterferon alpha-2a was higher than with 
conventional IFN (22-30% versus 10%, respectively)(l4). The increased rate of dose reductions with 
pegylated interferons seems mainly due to the increased occurrence of neutropenia. 
Untill now it was unknown whether PEG-IFN-induced neutropenia and thrombocytopenia indeed lead 
to an increase of bacterial infections and bleeding complications, respectively. In our study a 
neutropenia ofless than <L5xl09 /L significantly increased the risk of bacterial infections (Table 5). 
However, the number of bacterial infections was rather low and the infections were relatively mild. 
Only one serious infection (salmonella gastroenteritis) occurred in a patient with neutropenia above 
grade L The risk of bleeding complications was increased in patients with more severe 
thrombocytopenia, especially in patients with preexistent cirrhosis and platelets dropping below 75 x 
109 u/L. However bleeding complications were generally mild (epistaxis). Only one potentially life-
threatening bleeding complication (bleeding duodenal ulcus) occurred in a patient with mild liver 
fibrosis. 
We also investigated the course of side effects and adherence to therapy over time. Side effects were 
most pronounced at the beginning of therapy and subsided over time. They were generally well 
tolerated, but flu-like symptoms or depression in some cases necessitated dose reduction. Informing 
patients about the course of these adverse events and adequate treatment with paracetamol and specific 
serotonine reuptake inhibitors (SSRI's) may lead to an increased proportion of patients able to 
complete the treatment Neutropenia and thrombocytopenia are another frequent cause for dose 
reduction. Considering the mildness and rareness of complications of neutropenia in our patients, it 
might be worth wile to investigate in a randomized study if it is safe to accept grade 3 neutropenia 
without dose reduction during PEG-IFN treatment for chronic hepatitis B. Since, in our study, 
particularly cirrhotic patients were at an increased risk of thrombocytopenia and (minor) bleeding 
complications we would reconnend to monitor them closely and avoid a decrease in platelet count 
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below 75x 109/L. In a previous study in 217 cirrhotic patients with chronic hepatitis C treated with 
peginterferon alpha-2a, despite substantial decreases in neutrophil and platelet counts, episodes of 
infection and bleeding were mild and the treatment was reported to be safe for this patient population 
(21). 
In conclusion, treatment with PEG-IFN for chronic hepatitis B is safe and has a comparable side effect 
profile to conventional IFN. All adverse events were reversible after treatment discontinuation. Adding 
lamivudine to PEG-IFN did not affect PEG-IFN related side-effects. Hematological abnormalities 
during PEG-IFN treatment led to an increased risk of minor infections and bleeding complications. 
Cirrhosis and low neutrophil count at baseline are independent predictors of dose reduction or therapy 
discontinuation. In our opinion, one should be reluctant to initiate PEG-IFN treatment in cirrhotic 
patients. 
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Abstract 
Data on the long-term effects of alpha-interferon (IFN) treatment on disease progression and mortality 
in patients with chronic hepatitis B (CHB) are limited. To evaluate factors that influence clinical 
outcome and survival, we performed a follow-up study on 165 hepatitis B e antigen (HBeAg)-positive 
CHB patients, treated with IFN in Rotterdam between 1978 and 2002. The median IFN dose was 30 
megaunits (MU)/week (range 2-70 MU/week), the median duration of therapy 16 weeks (range 1-92 
weeks). Response to treatment was defmed as HBeAg loss within 12 months after the end of IFN 
therapy. Median follow-up was 8.8 years (range 0.3-24 years). Fifty-four patients (33%) responded to 
IFN treatment. Relapse (HBeAg reactivation) occurred in 7 of the 54 (13%) responders. Fifty-two 
percent of the responders lost Hepatitis B surface antigen (HBsAg) as compared to 9% of the non-
responders (p<0.001). Liver histology showed a decreased necroinflamrnatory activity and less 
progression of fibrosis in responders. Twenty-six patients died during follow-up. Hepatocellular 
carcinoma (HCC) was found in 8 patients, of which 6 were non-responders. Of the two responders that 
developed HCC, one patient had relapsed after discontinuation of therapy. Multivariate analysis 
showed a significantly improved survival (Relative risk (RR) of death 0.28, 95% CI 0.10-0.78) and 
reduced risk of developing hepatocellular carcinoma (HCC) (RR 0.084, 95% CI 0.09-0.75) in 
responders. In conclusion, response to IFN therapy results in a prolonged clinical remission with an 
increased rate of HBsAg seroconversion and improved liver histology. Our results indicate that, after 
correction for baseline factors, response to IFN therapy inreases survival and reduces the risk of 
developing HCC. 
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Introduction 
Chronic hepatitis B (CHB) affects 400 million people worldwide and is a major cause of morbidity 
and mortality. Patients with CHB are at an increased risk of developing liver cirrhosis and its 
complications such as hepatic decompensation and hepatocellular carcinoma (HCC), compared to 
matched controls from the normal population (1-5). During their lifetime, 25%-40% of CHB patients 
will develop serious complications (5). Treatment of CHB aims at inactivation of liver disease as 
indicated by hepatitis B e antigen (HBeAg) seroconversion and disappearance of HBV DNA, 
measured by hybridization techniques. Spontaneous HBeAg seroconversion occurs in about 8-12 % 
per year (6-8). Interferon alpha (IFN) has been reported to increase the HBeAg seroconversion rate to 
33% (8). Particularly in Caucasians data on the long-term effects on disease progression and mortality 
are limited. To further evaluate factors that influence clinical outcome and survival, we performed a 
retrospective cohort study on all HBeAg-positive CHB patients treated with IFN in our liver unit. 
Patients and methods 
Patients 
Patients were identified through a search of our trial databases and our computerized hospital-wide 
patient information system. All HbeAg-positive chronic hepatitis B (CHB) patients that were treated 
with interferon between 1978 and 2002 were included in the study. CHB was documented by hepatitis 
B surface antigen (HBsAg) positivity for more than 6 months and by a liver biopsy. We identified a 
total of 165 HBeAg positive patients that were treated with IFN in our center. One hundred thirty-two 
patients participated in one or more trials (9-16), the remaining 33 patients were treated electively. 
Sixty-two patients (38%) received treatment with nucleoside analogues as combination therapy with 
IFN (zidovudine (n=12), aciclovir (n=lO) and lamivudine (n=40), one patient received two courses of 
combination therapy). Forty-eight non-responders were retreated and received two or more courses of 
IFN. Patients were seen every 2-4 weeks during treatment. Thereafter patients were scheduled for 
visits every 3-12 months. Response was defmed as loss ofHBeAg at two consecutive measurements at 
least one month apart, during therapy or within 12 months after the end of the first IFN therapy. All 
other patients were considered non-responders. 
Follow-up 
Data were collected by review of patient records. We contacted all patients and asked them to return 
for evaluation and laboratory examination. If a patient could not be traced, relevant information was 
obtained from the patient's primary care physician. Data were collected on survival, occurrence of 
decompensated liver disease (defmed as ascites, encephalopathy, variceal bleeding or bilirubin> 34 
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fllllOl/1) and HCC. Of all patients that died the exact date and cause of death were documented. Follow-
up time was calculated from the start of IFN treatment until death or until the last visit. Secondary end 
points were occurrence ofliver disease related complications (HCC, decompensated liver disease). For 
calculation of survival times liver transplantation was combined with death. Of 16 patients no recent 
information was available. Only one of these patients had cirrhosis at the last biopsy, but minimal 
inflammatory activity. None of the patients that were lost to follow-up showed any signs of 
decompensated liver disease or HCC at the last visit. 
Measurements 
We reviewed biochemical data (ALT, AST, bilirubin and albumin) and virological data from the 
patient records. These tests were routinely performed at each visit to our outpatient clinic. For 
measurement of HBV DNA samples obtained pretreatment, one year posttreatment and at follow-up 
were retested. HBV DNA was assessed by TaqMan real-time PCR assay (17) (dynamic range 373 -
1010 geqlml, Eurohep standard). HBeAg, HBsAg, antibodies to HBeAg and antibodies to HBsAg were 
measured using enzyme-linked immunnnosorbent assays or solid-phase radioimmunoassays (Abbott 
Laboratories, Abbott Park, Il., USA). Liver biopsies were obtained at the start of therapy. For follow-
up the most recent liver biopsy was used. All liver biopsies were scored for inflammatory activity 
(combined score for portal inflammation and interface hepatitis) and fibrosis by two experienced 
pathologists using predefmed criteria. Inflammatory activity was scored as none(O), minimal(l), 
mild(2), moderate(3) and severe(4). Fibrosis was scored as none(O), mild(l), moderate(2), severe(3), 
probable cirrhosis(4) and cirrhosis(5). 
Statistics 
The Chi- square test was used to compare frequencies, the Marm-Whitney test to compare means 
between groups for various variables. The Kaplan-Meier (KM) method was used to estimate survival, 
and time to HBeAg and HBsAg seroconversion. The following variables were considered for 
univariate analysis: age; sex; baseline AST, ALT, albumin, bilirubin and HBV DNA levels; 
necroinflammatory and fibrosis score on liver biopsy; liver cirrhosis; mean weekly dose, total dose of 
IFN therapy and combination therapy with other antivirals. Response was analyzed as a time 
dependent factor. Patients who responded might have longer survival times, because they lived at least 
until response. To avoid this bias response was entered as a time-dependent covariate, i.e. all patients 
were entered in the non-responder group at the start of therapy, and, in case of response, were censored 
from the non-responder group at the time of response and included in the responder group (18). Cox 
regression analysis was applied to determine which factors were independently associated with 
survival. First, all baseline factors that were related to survival in the univariate analysis with p<O.IO 
were assessed by both the forward stepwise and backward stepwise method. Then baseline factors that 
predicted death were entered in a multivariate model together with the time-dependent factor response 
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to therapy. The same analysis was performed for the secondary endpoints decompensated liver disease 
and HCC. P-values are based on likelihood-ratio statistics. To exclude a confounding effect of 
coinfection with HCV, HDV or H1V survival analyses were repeated after exclusion of patients with 
these coinfections. All analyses were performed using SPSS version 10.1 (SPSS inc, Chicago, Il, 
USA). 
Results 
Baseline characteristics 
Baseline characteristics of the patients are shown in table 1. The patient group consisted of 165 
patients, of which 118 (72%) were male and 123 (75%) were Caucasian. The median ALT level was 
89 U!L (range 12-730). The median dose ofiFN was 30 MU/week (range 2-70 MU /week), the median 
duration of therapy was 16 weeks (range 1-92 weeks). 
Table 1 Baseline characteristics 
Age (years)* 
Male(%) 
Race(%) 
Caucasian 
Asian 
Other 
Mode of transmission(%) 
Vertical 
Parenteral 
Sexual 
Unknown 
ALT (U/1)* 
AST (U/1) * 
Bilirubin (f.Ullol/1) * 
Albumin (g/1) * 
LogHBVDNA 
Cirrhosis (%) 
IFN dose (MU) * 
Mean weekly IFN dose * 
Follow-up (years)* 
*median (range) 
Total (n = 165) Responders (n= 54) 
34 (10-67) 37 (10-64) 
118 (71.5) 41 (75.9) 
123 (74.5) 45 (83.3) 
32 (19.4) 6 (11.1) 
10 (6.0) 3 (5.6) 
13 (7.9) 3 (5.6) 
13 (7.9) 4 (7.4) 
60 (36.4) 21 (38.9) 
79 (47.9) 26 (48.2) 
89 (12-730) 102 (21-730) 
46 (12-367) 59 (15-264) 
11 (2-45) 12 (5-32) 
43 (14-54) 42 (14-50) 
9.0 (3.5- 10.1) 8.5 (3.5-9.9) 
30 (19) 15 (29) 
510 (33-3130) 504 (55-3130) 
30 (2-70) 30 (9-36) 
8.8 (0.3- 23.9) 10.6 (0.8-19.5) 
Non-responders (n= 111 p-va1ue 
32 (16-67) 
77 (69.4) 
78 (70.3) 
26 (23.4) 
7 (6.3) 
10 (9.0) 
9 (8.1) 
39 (35.1) 
53 (47.7) 
81 (12-654) 
41 (12-367) 
11 (2-45) 
44 (28-54) 
9.1 (4.2-10.1) 
15 (14) 
510 (33-1650) 
30 (2-70) 
7.9 (0.3-23.9) 
0.081 
0.38 
0.056 
0.91 
0.020 
0.002 
0.91 
0.057 
0.080 
0.034 
0.864 
0.254 
0.2756 
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Forty-eight patients, 45 non-responders and 3 responders who relapsed, were retreated with IFN: 33 
patients received 2 courses of IFN, 8 patients 3 courses, 5 patients 4 courses, and 2 patients 5 courses. 
Median follow-up time was 8.8 years (range 0.3-23.9 years). Coinfection with HCV, HDV and HIV 
was present in 3, 2, and 7 patients, respectively. 
Follow-up 
Virological response: Of all 165 patients 54 patients (33%) exhibited a response. Recurrence of 
HBeAg was seen in 7 of the responders (13%). Responders had a significantly higher pretreatment 
ALT level than non-responders (median 102 U/1 (range 21-730 U/1) vs 81 U/1 (range 12-654 U/1), 
respectively, p=0.02). Patients with preexisting cirrhosis (n=30) had a higher response rate than 
patients without cirrhosis (50% vs 29%, p=0.026). At the end of follow-up HBV DNA was negative 
by PCR in 61 patients (43%). Responders significantly more often exhibited loss ofHBsAg (52%) and 
HBV DNA (70 %) than non-responders (9% and 30% respectively, p<0.001). The time to loss of 
HBeAg and HBsAg in responders and non-responders is shown in figure 1. Among the 111 non-
responders, 57 patients lost HBeAg during follow-up. Of these patients 17 lost HBeAg within a year 
after retreatrnent with IFN and 40 patients exhibited a spontaneous loss ofHBeAg. 
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Figure 1 Time to HBeAg-loss (A) and HBsAg-loss (B) of responders compared to non-
responders. Responders exhibited HbeAg-loss during or within a year after the first course of 
IFN. 
ALT normalization: ALT levels at the end of follow-up were significantly lower in the group of 
responders (median ALT 21 UIL vs 35 UIL, p=O.OOl). In the responder group 39 of the 54 patients 
(72%) had a normal ALT at the end of follow-up, compared to 63 of the 111 (57%) non-responders. 
This difference tended towards significance (p= 0.055) 
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Liver histology: At the start of therapy, 155 patients underwent a liver biopsy. Of 123 patients paired 
liver biopsies were available (mean follow-up time 3.1 years, range 0.4-14.6 years). At baseline, 
responders had higher inflammatory activity (mean score 2.4 vs. 2.1, p=0.006) and more advanced 
fibrosis (mean score 2.4 vs. 1.6, p=O.OOl) than non-responders. Inflammatory score improved in 30 of 
43 responders (70%) and in 27 of 81 non-responders (33%) (p<O.OOl), mean score at follow-up was 
1.6 in responders vs. 2.0 in non-responders (p=O.Oll). In the responder group, less patients had 
progression of fibrosis (8 of 42 responders (19%) vs. 35 of 81 non-responders (43%), p=0.039). Also 
more responders showed an improvement in fibrosis score (12 of 42 responders (29%) vs 13 of 81 
non-responders (16%)), but this difference did not reach statistical significance (p=O.l). 
Survival 
In 18 patients complications of CHB occurred (HCC and/or decompensation of liver disease). Two 
patients underwent liver transplantation, one of whom died of transplantation related complications. 
One patient underwent a partial liver resection for HCC, but had a recurrence thereafter. Two patients 
died on the waiting list for liver transplantation. The other patients had inoperable HCC (n=6) or were 
not eligible for transplantation because of comorbidity, high age or clinical condition (n=7). Twenty-
six patients died during follow-up, 16 of complications of liver disease, and 10 of unrelated causes. 
Overall, five-year survival was 90% (95% CI: 86%-94%), ten-year survival was 84% (95% CI: 78%-
91 %). The survival of responders and non-responders is shown in figure 2. Overall, not corrected for 
baseline factors, there was no difference in survival between responders and non-responders (Fig 2A). 
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Figure 2 Survival among responders and non-responders to IFN, overall (A) and stratified for 
preexisting cirrhosis (B). All patients were entered as non-responders at start of therapy, with 
response as a reason for data censoring. Survival of responders was calculated from time of 
response. 
However, the percentage of patients with cirrhosis in the responder group was twice as high as in the 
non-responders (29% and 14%, respectively), giving the responders a priori a substantially higher 
mortality risk When analyzed separately for patients with and without preexisting cirrhosis, survival 
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was improved in both groups for patients responding to IFN (Fig 2B). In the univariate analysis of all 
165 patients, the baseline factors sex, age, AST, bilirubin, albumin, cirrhosis, liver inflammation and 
mean weekly IFN dose were related to survival (p<O.l) (Table 2). To correct for possible changing 
treatment schedules and inclusion criteria over time we stratified for 5-year cohorts, but survival was 
not different between these cohorts. To evaluate the effect of combination therapy with lamivudine 
(n=40), zidovudine (n=l2) or aciclovir (n=lO), we stratified for these therapies. Only zidovudine 
combination therapy was associated with survival (worse survival with zidovudine), but this can be 
explained by the fact that this group included 3 patients with HN coinfection. The factors related to 
survival in univariate analysis were then included in the multivariate analysis. In this analysis the 
baseline factors sex, age, albumin and cirrhosis were independently associated with death. Then 
response was entered in a multivariate model as a time-dependent factor together with these baseline 
factors. Corrected for the above baseline factors, response to therapy significantly improved survival 
(Table 3). Response was associated with a significantly decreased risk of HCC, but not of 
decompensated liver disease. When we repeated the analysis for patients without cirrhosis, survival 
was still significantly improved in responders (p=0.007). Exclusion of the small number of patients 
with HCV (n=3), HDV (n=2) and HIV (n=7), did not influence the analysis. Also excluding patients 
treated with low (<15 MU) and high (>45 MU) weekly doses ofiFN did not influence the outcome. 
We then analyzed whether spontaneous HBeAg loss influenced survival in the non-responder group. 
Among the non-responders survival was significantly improved in patients that exhibited spontaneous 
HBeAg loss compared to patients that remained HbeAg-positive (RR 0.11, p=0.04). The time to 
HBeAg loss was not a predictor of survivaL 
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Figure 3 Development of decompensated liver disease (A) and HCC (B) among responders and 
non-responders to IFN, stratified for preexisting cirrhosis. All patients were entered as non-
responders at start of therapy, with response as a reason for data censoring. Survival of 
responders was calculated from time of response. 
The development of decompensated liver disease and HCC is shown in figure 3. HCC occurred in 8 
male patients. Among the 111 non-responders six patients (5.4 %) developed HCC after a median 
interval of 2.2 years (range 0.8-14.4 years). In the responder group two of the 54 patients (3.7%) 
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developed HCC after 9.5 and 4.1 years of follow-up. Of the two responders that developed HCC, only 
one patient had a lasting response to therapy, the other relapsed after discontinuation of therapy. As 
mentioned above, response also significantly reduced the risk of developing HCC in a time-dependent 
multivariate analysis (Table 3). 
Table 2 Univariate analysis ofbaselinefactors. Kaplan-Meier estimates of survival compared by log-
rank testing. 
n 5-year survival(%) p-value 
Sex Male 118 87 0.009 
Female 47 100 
Age <35 90 95 0.003 
~35 75 84 
Race Caucasian 123 88 0.20 
Asian 32 97 
Transmission vertical 13 100 0.16 
sexual/ parenteral 73 86 
AST < 1.5xULN 93 93 0.087 
~ 1.5xULN 70 86 
ALT <2xULN 66 94 0.17 
~2xULN 95 88 
Bilirubin <10 62 97 0.02 
~10 97 87 
Albumin <40 38 70 <0.001 
~40 121 97 
LogHBVDNA <9 66 89 0.35 
~9 67 92 
Inflammation (biopsy) None-Mild 100 96 0.003 
Moderate- Severe 56 80 
Cirrhosis Absent 125 95 <0.0001 
Present 30 67 
Combination therapy No 102 91 0.66 
Yes 62 89 
Mean weekly 1FN dose <30MU 59 88 0.08 
~30MU 105 92 
Total dose ofiFN < 510 MU 81 88 0.47 
;::: 510 MU 83 94 
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Table 3 Predictive factors for death, decompensated liver disease and HCC: multivariate Cox analysis 
Death Decompensated liver HCC 
(n=27) disease (n= 16) (n=8) 
Variables RR(95%CI) p-value RR(95%CI) p-value RR(95%CI) p-value 
Age 1.04 (1.01-1.07) 0.022 1.10 (1.03-1.18) 0.003 1.07 (1.01-1.13) 0.032 
Sex 0.17 (0.02-1.28) 0.027 
Albumin 0.88 (0.82-0.94) 0.002 0.79 (0.67-0.92) 0.003 
Cirrhosis 2.68 (1.12-6.37) 0.025 8.06 (1.97-33.0) 0.003 9.62 (1.76-52.5) 0.009 
Response 0.28 (0.1 0-0. 78) 0.008 0.08 (0.01-0.75) 0.027 
Discussion 
Treatment with IFN has been reported to increase the HBeAg seroconversion rate and induce disease 
remission in patients with CHB. In our study 33% of patients lost HBeAg within one year after the end 
of therapy, which is comparable to the response rates found in other studies (7,8,19). We also found a 
high rate ofHBsAg loss (52%) in patients who exhibited HBeAg loss after IFN therapy, as has been 
described before particularly in Caucasians (20,21). However, the long-term effects ofiFN therapy on 
morbidity and mortality are controversial. In our study, we found a significantly prolonged survival in 
patients who responded to IFN. A number of studies have reported the long-term clinical course of 
CHB patients treated with interferon. Most studies compared the survival of IFN treated patients to 
untreated controls (2,18, 21-23). Among these studies, two were randomized controlled trials (21-22), 
the others were cohort studies with a control group. Di Marco et al. reported a better overall survival 
and complication-free survival after IFN treatment in Italian patients (2). However this study included 
both HBeAg-positive and -negative patients, and patients with coinfections. Also, the different groups 
were not fully comparable, as treated patients had significantly higher baseline ALT levels than 
untreated controls. In Asian patients Lin et al. found a prolonged survival, and a decreased incidence 
of HCC in IFN treated patients (22). In our study the majority of deaths were due to complications of 
liver disease. We that the risk of developing HCC was decreased in responders to IFN, when all 
independent predictors of complications of liver disease were included in the multivariate analysis. As 
we found no significant difference in occurrence of decompensated liver disease, the survival benefit 
of response in our patients may be explained by the decreased incidence ofHCC. Because of the small 
number of patients developing HCC in our study (n=8) the analysis of this endpoint should be 
confirmed in future studies. Considering the disease remission following response to IFN treatment, 
one might expect a prolonged survival and less REV-related complications in IFN treated patients. 
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Particularly, in Caucasian patients even after long-term follow-up the proportion of patients with 
disease remission (HBeAg-negative, HBV DNA-negative, normal ALT levels) remains higher in IFN 
treated patients (18-20). In patients with preexisting cirrhosis HBeAg clearance and biochemical 
remission have been reported to be predictors of survival (24,25). Niederau et al also reported 
prolonged survival and a decreased risk of complications ofliver disease after HBeAg-clearance (18). 
Nevertheless, two large studies, one in a predominantly Caucasian patient group (21), one in Asians 
(23), found no difference in survival or liver related complications between IFN treated patients and 
controls. The difference between the results of these studies and our current study may be explained by 
several factors. Firstly, the limited follow-up of studies and the slow natural course of the disease. In 
patients with active disease and minimal fibrosis who remain untreated or do not respond to IFN 
therapy the development of liver cirrhosis and its complications may take considerably longer than the 
mean follow-up in most of these previous studies. Only the study ofYuen et al. (23) had a comparable 
follow-up time to our study (median follow-up 9 years), but due to the very young patient group 
(median age 27 years, much lower than in all other studies) the incidence of complications was low. 
Secondly, the different study design of most previous studies. Several studies compared IFN treated 
patients to untreated controls. However, a long-term benefit of IFN therapy might only occur in 
patients who exhibit IFN-induced HBeAg loss. As a consequence of the limited response rate to IFN 
(30-40%) this would make the benefit of therapy difficult to prove when the whole treated group is 
compared to untreated controls. Our study aims to overcome these difficulties by a longer follow-up 
time than in previous studies, and by comparing IFN responders to non-responders. In this approach 
one has to take into account that responders to IFN tend to have more disease activity than non-
responders (higher ALT, more infla=ation on liver biopsy). In addition, the percentage of cirrhotic 
patients among responders was two times higher than in non-responders. These patients with 
preexisting cirrhosis clearly exhibited a substantially increased risk of complications and mortality. 
Using a multivariate time-dependent analysis, correcting for cirrhosis and other baseline factors, we 
found a significantly better survival in responders to IFN. Also if we analyzed patients without 
cirrhosis separately we found an improved survival after response to IFN. To exclude a confounding 
effect of retreatment with IFN in non-responders survival analyses were repeated after data censoring 
at the start of a second IFN course. After censoring patients at the start of retreatment with IFN, 
response remained significantly associated with survival. Also the survival of patients who received 
one course of therapy was not significantly different :from patients who received two or more courses 
ofiFN. Our results are supported by the fmdings ofLau et al (20), who reported a better complication-
free survival in patients who responded to IFN treatment compared to non-responders, when cirrhosis 
was considered in the analysis. In our opinion the durability of response to IFN, high HBsAg-
seroconversion rate after response, combined with the improved long-term clinical outcome justifies 
the use ofiFN as first-line therapy for HBeAg-positive CHB patients with compensated liver disease. 
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We conclude that in CHB patients response to IFN therapy results in a prolonged clinical remission 
with an increased rate of sustained HBsAg seroconversion and improved liver histology. Our results 
indicate that, after correction for baseline factors, response to IFN therapy increases survival and 
reduces the risk of developing HCC. 
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Abstract 
Polyarteritis nodosa (PAN) is a systemic inflammatory disease causing vasculitis of medium sized and 
small arteries. Circulating immune complexes containing viral proteins have been implicated in the 
pathogenesis of HBV -related PAN and several immunosuppressive and antiviral regimens have been 
used with varying success. In our hospital seven HBV positive patients with a confrrmed diagnosis of 
PAN could be identified between 1984 and 2001. Most patients had an acute HBV infection and all 
patients were treated with prednisone. Only in the last four patients prednisone was combined with 
antiviral therapy with alpha-interferon (IFN). HBV DNA was isolated 'from serum samples obtained 
pre-treatment from the four IFN-treated patients and amplified by polymerase chain reaction (PCR). 
None of the patients without, but 2 of 4 with antiviral therapy exhibited HBsAg seroconversion. In 3 
out of 4 patients HBV DNA decreased rapidly after starting IFN -therapy. Clinical remission of PAN 
was observed in 3 of the 4 treated patients, but in none of the 3 patients who lacked treatment with 
antiviral medication. Analysis of the HBV genome revealed no mutations, which could be associated 
with PAN. In one patient a stop codon in the precore region and a double mutation Al7662T-Gl764A 
were found during antiviral therapy. We did not find HBV heterogeneity predisposing to the 
development ofP AN. 
In our group of patients it appeared that clinical remission of PAN was primarily related to - spon-
taneous or therapy-induced- loss ofHBV DNA replication. The combined administration of a priming 
steroid course and IFN appears an improvement over prednisone monotherapy and should be 
considered for every patient with HBV-related PAN. The efficacy of new generation nucleoside 
analogues should be further elucidated in future studies. 
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Introduction 
Polyarteritis nodosa (PAN) is an unco=on systemic infla=atory disease caused by a necrotizing 
vasculitis of the medium sized and small arteries. The predominant clinical manifestations of PAN are 
abdominal pain, fever, weight loss, hypertension, arthritis, neuropathy and renal failure (1,2). The 
diagnosis of PAN is based on criteria described by the American College of Rheumatology (ACR), 
including histologic or angiographic evidence of vasculitis and a spectrum of clinical findings (3). 
Nevertheless, the varying clinical presentation and the rarity of the disease often lead to a considerable 
interval between appearance of initial symptoms and diagnosis of PAN. If left untreated PAN has a 
poor prognosis with a 5-year survival rate of 20% ( 4). Approximately 7% of the patients with PAN are 
hepatitis B surface antigen (HBsAg) positive. Most of them are diagnosed with PAN in the acute phase 
of the hepatitis B virus (HBV) infection. Although viral circulating immune complexes have been 
implicated in the pathogenesis of HBV -related PAN the exact cause of the vasculitic lesions remains 
obscure (5). A recent case of PAN and HBeAg-negative HBV infection due to a mutation in the pre-
core promotor region, suggests that responsible immune complexes do not necessarily include HBeAg 
(6). PAN is a therapeutic challenge and several immunosuppressive and antiviral regimens have been 
used with different success. In this paper we report on our experience of combined therapy of predni-
sone and IFN in PAN associated with hepatitis B infection, and we address the question whether hete-
rogeneity in the HBV genome could predispose to PAN. 
Case Reports 
Case identification 
Presumed Diagnosis PAN 
n=45 
I 
Confirmed Diagnosis PAN (ARC) 
n=32 
H 
I m m 
HBV positive HBV not known HBV negative 
n=7 n=6 n=l9 
• B m 
AVT noAVT 
n=4 n=3 
Figure 1 Identification of patients with HBV related PAN 
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We performed a search for patients registered with the diagnosis of PAN between 1984 and 2001 in 
our computerized hospital registration system. A total of 45 patients were identified. In 32 of them the 
diagnosis of PAN could be confirmed following the ACR criteria (3). Of these 32 patients 7 (22%) 
were HBV positive (figure 1). All HBV patients were treated with prednisone. In addition, four 
patients underwent antiviral therapy for HBV infection: 
Table 1 Laboratory values at referral to our hospital. 
Case 1 Case2 Case3 Case4 normal 
values 
ESR (mm/hour) 82 80 18 51 0 -10 
Hemoglobin (mmol/l) 7.5 6.6 7.8 6.8 8.2-10.2 
Leukocytes (x 109/l) 17.9 23.0 6.8 12.5 4.0-10.0 
Platelets (x 109/l) 369 114 280 505 140-360 
ALT (U/l) 46 61 157 37 5-30 
AST (U/l) 23 54 136 45 5-30 
Alkaline fosfatase (U/l) 347 904 404 60 25-75 
Gamma-GT (U/l) 128 213 115 33 5-35 
Bilirubin (micromol/l) 11 26 19 10 4- 14 
Albumin (gil) 29 20 36 35 36-48 
Creatinin (micromolll) 56 365 101 104 60- 110 
Urea nitrogen (U/l) 8.3 11.3 5.1 7.1 3.0- 8.0 
Case 1 was a 39-year old male admitted elsewhere with fatigue, fever and a weight loss of 20 kg. One 
year previously, he attempted suicide by taking an overdose of diazepam. Otherwise his previous 
history was unremarkable. Three weeks after onset of disease, he developed a tachycardia, hyperten-
sion (160/110 mmHg) and tetraparalysis with hyporeflexia and distal sensory impairment. He was 
referred to our hospital. Laboratory results showed a mild hepatitis (table 1). He was serum HBsAg, 
HBeAg and IgM anti-HBc positive indicating an acute hepatitis B infection. Serum HBV DNA level 
was 2.5xl09 genomes per rnl (Digene assay). Electromyography was suggestive of mononeuritis 
multiplex and muscle biopsy showed necrotising vasculitis of medium- and small-sized arteries. Liver 
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biopsy revealed a mild hepatitis and steatosis without evidence of vascultits. Abdominal angiography 
was normaL After psychiatric consultation he was started on prednisone 60 mg. Prednisone was tape-
red and discontinued after 3 months. One month after start of prednisone IFN 9 MU ti.w. was 
introduced. There was a rapid decrease in HBV DNA level, which was accompanied by a transient rise 
in aminotransferase values and subsequently by an HBe- and HBsAg seroconversion (figure 2). Within 
the following months the patient exhibited a gradual but spectacular clinical improvement with 
disappearance of neurological symptoms. At present, 1.5 year later, he is in complete remission and 
able to walk again. 
Case 2 was a 30-year old male who developed jaundice, arthralgias and anorexia after visiting a 
prostitute. Two months later the icterus had subsided but he complained of pain and hyposensibility in 
hands and feet. In addition he had developed fever, hypertension (160/100 mmHg) and paralysis of the 
peroneal nerve caused by mononeuritis multiplex. Laboratory fmdings showed severe renal impair-
ment and slightly elevated liver enzymes (table 1). HBsAg, HBeAg, IgM anti-HBc and HBV-DNA 
(9.9x109 genomes/ml) in serum were positive. Liver biopsy revealed moderate hepatitis with minimal 
fibrosis. Renal angiography showed microaneurysms and small infarcts consistent with PAN. A few 
days after administration of 100 mg prednisone he experienced a grand-mal seizure for which depa-
kine was given. One month after start of prednisone, IFN 9 MU t.i.w. and lamivudine 150 mg p.o. 
daily were added. Although HBV-DNA dropped considerable, HBeAg remained positive (figure 2). 
His complaints did not disappear. In the period thereafter prednisone was gradually reduced and 
although his neurological status slightly improved, renal function deteriorated. Two months after start 
of antiviral therapy he was readmitted with rapidly developing dyspnea and respiratory failure due to 
pneumocystis carinii infection. He died 3 days later. 
Case 3 was a 56-year old male who was hospitalized elsewhere with a hepatitis B infection, complica-
ted by mononeuritis multiplex and a 5 kg weight loss. The duration of HBV infection was unknown. 
The patient was married to a heart transplantation recipient who was accidently infected with HBV. At 
referral to our hospital, 3 months after the initial symptoms, he was still invalidated by fatigue, hypo-
sensibility and motoric disturbances of the extremities. Lab results showed a mild hepatitis and active 
HBV replication (HBeAg positive, HBV DNA 8.2x108 genomes/ml) (table 1). Vasculitis was 
confirmed by sural nerve biopsy. Abdominal angiography was normaL He was treated with a course of 
prednisone (tapered from 60 mg per day) in combination with IFN 10 MU t.i.w. There was no 
response to IFN therapy, which had to be discontinued prematurely because of severe anorexia and 
weight loss (figure 2). Spontaneous HBeAg seroconversion occurred 2.5 years after IFN had been 
stopped. HBsAg remained positive. During the last year the patient exhibited a full clinical recovery. 
Case 4 was a 29-year old homosexual male who developed abdominal pain and fatigue. At 
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his local hospital acute hepatitis B infection was diagnosed (IgM anti-HBc positive). During the 
following two months he complained of dizziness, visual disturbances and periorbital numbness. In 
addition, he developed hypertension (160/110 mm Hg) with impaired renal function and proteinuria 
(2.4 g/1) (table 1). Minimal liver function abnormalities were found. HBeAg and HBV DNA (1.2xl09 
genomes/ml) in serum were positive. Magnetic resonance imaging of the brain demonstrated ischemic 
lesions in the medulla oblongata and the periventricular area. Retinal exsudates and sclerotic vessels 
were seen on ophtalmic examination. Electromyography showed mononeuritis multiplex and neuro-
muscular biopsy revealed necrotizing vasculitis. Abdominal angiography was unremarkable. Predni-
sone was started at 60 mg and slowly withdrawn in weeks. Simultaneous with the start of prednisone 
he received a 9-month IFN course with doses varying from 3 to 9 MU t.i.w. After prednisone was 
stopped there was a double transaminase flare leading to loss of serum HBV-DNA in combination 
with HBeAg and HBsAg seroconversion (figure 2). With virus eradication he underwent a clinical 
improvement. At the moment, 4 years later, he is still treated for hypertension. All other manifestations 
ofPAN have disappeared. 
Table 2 Characteristics and clinical outcome of patients with and without antiviral therapy 
Symptoms Immunosuppression antiviral Outcome PAN outcomeHBV 
therapy 
Weight loss, muscular Prednisone IFN Partially resolved HBeAg/HBsAg 
weakness, mononeuritis seroconversion 
multiplex, hypertension 
Weight loss, myalgia, Prednisone IFNI Died HBeAg positive 
mononeuritis multiplex, Lamivudine 
hypertension, renal failure, 
micro-aneurysms 
Weight loss, muscular Prednisone IFN Remission HBeAg 
weakness, mononeuritis seroconversion 
multiplex 
Weight loss, mononeuritis Prednisone IFN Remission, still treated for HBeAg!HBsAg 
multiplex, hypertension, renal hypertension seroconversion 
failure, 
Hypertension, renal failure, Prednisone/ Endoxan 
-
Renal transplantation HBeAg 
vasculitis seroconversion 
Hypertension, renal failure, Prednisone - Renal transplantation HBeAg 
vasculitis seroconversion 
Weight loss, polyneuropathy, Prednisone/ Endoxan - Died unknown 
testicular pain 
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Characteristics and clinical outcome of these 4 patients undergoing antiviral therapy and of the 
remaining 3 who were only treated with immunosuppressive agents are given in table 2. In summary, 
none of the patients without, but 2 of 4 with antiviral therapy exhibited HBsAg seroconversion. No 
clinical remission of the PAN was observed in the 3 patients with acute HBV infection who lacked 
treatment with antiviral medication. Two of them developed HBeAg seroconversion but none HBsAg 
seroconversion. This suggests that HBsAg seroconversion indicating viral eradication is best 
associated with clinical remission ofPAN. 
HBV DNA genome analysis 
To investigate whether (a) REV-related PAN is associated with specific HBV gene mutations and (b) 
treatment outcome in PAN is associated with HBV variants we sequenced the entire HBV genome 
from all 4 IFN-treated patients. Pre-treatment serum HBV DNA was amplified by polymerase chain 
reaction (PCR) using the primers HBPr108 and HBPr109. For case 4 only on-treatment serum was 
available for sequence analysis. Sequencing was performed on an automated DNA sequencer as 
previously described (7). The sequencing primers were used according to Stuyver et aL (8). The HBV 
genome of the four treated patients was compared to a consensus sequence. Genotype A was found in 
case 1 and case 2, genotype D (serotype ayw3) in case 3, and genotype Gin case 4. The amino acid 
sequence of the pre-S1, pre-S2, HBsAg, precore, core and X open reading frame are shown in figure 3. 
No identical mutations were found in more than two patients. The following X gene mutations 
occurred in 2 patients: G1390A, Gl437A, A1574T, Al676T, Al703C, Tl741C, Cl449T/A, a 
1511G/T, G1634A/T and C1637G/T. In one patient (case 4) a stop codon mutation at nucleotide(nt) 
1896 was found (G1896A) during antiviral therapy. The same patient also had a double mutation 
A1762T-Gl764A in the basal core promoter gene. No identical repetitive mutations were found in the 
precore, core and polymerase gene. 
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Figure 3 Amino acid sequence alignment of the pre-Sl, pre-S2, HBsAg, precore, core and X open 
reading frame 
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Discussion 
As circulating viral immune complexes are probably of pathogenetic importance for the vasculitic 
lesions, it is thought that eradicating REV replication is essential in controlling the evolution of PAN. 
Conventional therapy of PAN consists of immunosuppression with steroids, cyclophosphamide and 
methotrexate, whether or not in combination with plasma exchanges (4,9). Immunosuppressive 
regimens have proven efficacy against the symptoms of vasculitis but perpetuate chronic REV 
infection. About one decade ago antiviral treatment was introduced for REV-related PAN. Prednisone 
combined with vidarabine led to a reduction of viral replication and to significant improvement of 
symptoms (1 0). Vidarabine, however, is not used anymore for this indication because of its neuro-
toxicity. 
In our group of 7 patients it appeared that clinical remission of PAN was primarily related to - spon-
taneous or therapy-induced - control of REV DNA replication. Recently the position of IFN as first-
line standard therapy for REV infection has been re-established. Previously, IFN-based regimens were 
found to be efficacious in several studies on REV-associated PAN (11-13). Guillevin et al. reported 
that prednisone-IFN therapy in combination with plasma exchanges resulted in a 50% REsAg 
seroconversion response and clinical remission (11). In our small series of patients with REV-related 
PAN the simultaneous administration of steroids and IFN with early discontinuation of steroids, was 
efficacious in 2 of 4 patients. Priming treatment with prednisone should initially control the manife-
stations of vasculitis while subsequent withdrawal will activate the cellular immune system and 
thereby facilitate the immune modifying effect of IFN necessary to clear the REV-infection. 
Previously, in two REeAg-negative patients a significant improvement of clinical symptoms after IFN 
therapy was described, with REsAg seroconvesion in one patient who had a precore promotor mutant 
REV infection (6,14). 
The clinical benefit of larnivudine on other novel nucleoside analogues in REV -related PAN is as yet 
not well described. A recent case report describes successful larnivudine therapy for a kidney 
transplant recipient who developed cutaneous PAN associated with the reappearance of REV 16 years 
after transplantation (16). Trepo et al. reported a good clinical response to lamivudine as single 
antiviral therapy (17). In contrast, Maclachlan reported a patient whose clinical signs worsened 
despite reduction of the viral load with lamivudine (18). If one considers sustained REeAg and 
REsAg seroconversion as a prerequisite for a full clinical response of PAN, lamivudine would appear 
less helpful than IFN (15). In contrast to IFN, therapy with larnivudine hardly augments a sustained 
immune response but merely suppresses viral replication. Therefore, lamivudine does not induce 
REsAg seroconversion and continued therapy leads to selection of drug resistant mutants as 
manifested by reappearance of REV DNA. 
Successful combination therapy of IFN and larnivudine has been reported in patients with chronic 
hepatitis Band in two cases with REV-related PAN (19-21). A patient who developed life-threatening 
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complications of PAN despite IFN (mono )therapy was successfully treated with a combination of IFN 
and lamivudine (22). The only patient from our group who was treated with both IFN and lamivudine 
did not respond and died. 
The role of heterogeneity of HBV in the development of PAN remains unclear. In our patients no 
association between a specific mutation and the development of PAN was found. One patient 
developed both a precore stop codon mutation and a mutation in the basal core promoter during 
antiviral therapy. These mutations have been associated with increased virulence. Despite the fact that 
precore mutations have been shown to negatively influence response to IFN, our patient showed a 
response with HBsAg seroconversion. 
In conclusion, our cases support the concept that clinical remission of PAN is primarily related to 
control of HBV replication. Based on our results and the available literature prednisone-IFN therapy 
maybe effective for REV-associated PAN. The efficacy of IFN and new generation nucleoside 
analogues must be further investigated in long-term follow-up studies, preferably in a multi-center 
controlled setting. Our data do not lend support to the concept that specific mutations in the HBV 
genome predispose to the development of PAN. 
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Summary and conclusions 
The treatment of chronic hepatitis B aims at the prevention of liver cirrhosis and its complications. 
Ideally, it would eliminate the virus completely (HBsAg seroconversion). The most frequently used 
measure of efficacy, however, is control of viral replication, either by (prolonged) suppression with 
antiviral drugs or without drugs after successful immune modulatory treatment. In the past years 
marked progress has been made in the treatment of chronic hepatitis B. At the start of this study in 
1999, the efficacy of treatment was still limited. The two registered drugs at that time were interferon 
alpha (IFN) and lamivudine. IFN is only effective in 20-35% of patients. For larnivudine the efficacy 
of treatment is limited by the emergence of resistant HBV mutants. Therefore there was a need for 
more effective treatment options. 
The high response rates achieved with pegylated forms of IFN in chronic hepatitis C have led to a 
renewed interest in IFN treatment for chronic hepatitis B. We studied the effect ofpeginterferon alpha-
2b (PEG-IFN) in a large randomzied trial, with participating centers from Europe, Asia and Canada. A 
total of 266 HBeAg-positive patients were evaluated after one year of treatment with PEG-IFN in 
combination with either larnivudine or placebo, and followed for six months thereafter. Our primary 
endpoint for the study was loss of serum HBeAg, because this is associated with durable virus 
suppression and normalization of AL T, as reported in earlier studies. We found that 3 6% of patients 
had lost HBeAg at the end of follow up (chapter 2). Although the rate of HBeAg loss at the end of 
therapy was higher in patients that received the combination ofPEG-IFN and lamivudine (44%) than 
in patients receiving PEG-IFN alone (29%), this was not sustained during follow-up. At the end of 
follow-up there was no difference in response between patients treated with PEG-IFN alone or in 
combination with lamivudine. Response rates were dependent on HBV genotype, with genotype A and 
B responding better than genotype C and D. Because HBV genotype is an important predictor of 
response to treatment, future studies should take genotype into account. Like in chronic hepatitis C, 
different treatment regimens may be needed for different genotypes. 
The effect PEG-IFN on liver histology was assessed at the end of treatment in 110 patients. We found 
that response (HBeAg negativity at the end of follow-up) to PEG-IFN therapy was also accompanied 
by histological improvement (chapter 3). At the end of therapy, necroinflammation had improved in 
half of the patients, but more often in responders (78%) than non-responders (43%). Fibrosis only 
improved in a minority of responders. However, the interval of one year between the biopsies may 
have been too short to achieve the full effect of therapy on liver fibrosis. 
With combination therapy of PEG-IFN and lamivudine a fast and profound virus suppression was 
achieved (chapter 4). During therapy with PEG-IFN alone viral decline was significantly less. 
Particularly responders showed a viral decline, and in a proportion of responders this only occurred 
after a variable delay of up to 32 weeks. We assessed ifHBV DNA decline or single HBV DNA levels 
at different timepoints during therapy could be used to predict response. We found that HBV DNA 
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level was best associated with response. Because of the different patterns of HBV DNA decline, a 
prediction of response could be made at week 4 of therapy for PEG-IFN combined with lamivudine 
and at week 20 of therapy for PEG-IFN alone. The chance of response was minimal if with 
combination therapy ofPEG-IFN and lamivudine the HBV DNA level was above 107 geq/ml (negative 
predictive value 93%) after 4 weeks of therapy. With PEG-IFN therapy alone this was the case if the 
HBV DNA level was above 109 geqlrnl after 20 weeks of therapy (negative predictive value 88%). 
These cut-offlevels might be used as "stopping rule". 
As PEG-IFN therapy has not been used previously in chronic hepatitis B patients we also assessed its 
safety in this patient population (chapter 5). The most common side effects were the same as those 
occurring with standard IFN (flu-like symptoms, headache, fatigue, myalgia, alopecia, gastrointestinal 
symptoms and psychiatric symptoms). These adverse events were most prominent during the first 
months of therapy. Hematological abnormalities were frequent but did not lead to serious 
complications. Dose reduction and discontinuation of treatment were necessary in 23% and 9% of 
patients, respectively. Half of the dose reductions were due to neutropenia, whereas the most frequent 
cause for treatment discontinuation was the occurrence of psychiatric symptoms (depression, 
psychosis). Neutropenia and liver cirrhosis at baseline were independent predictors of dose reduction 
and treatment discontinuation. Patients with preexistent cirrhosis were at an increased risk of 
thrombocytopenia and (minor) bleeding complications. All side effects were reversible after 
discontinuation of therapy. 
Although the beneficial effects of IFN therapy on disease activity have been well described, the effects 
on the development of complications related to liver cirrhosis and mortality are still less well defmed. 
Therefore we followed all hepatitis B e antigen (HBeAg)-positive CHB patients that were treated with 
standard IFN in Rotterdam between 1978 and 2002 (chapter 6). The median follow-up time in our 
study was 8.8 years. Of the 165 patients, 33% responded to IFN treatment. Responders to IFN showed 
an increased rate of HBsAg loss and less progression of liver fibrosis. Survival analysis showed that 
the risk of developing hepatocellular carcinoma was lower and survival was longer in responders to 
IFN. 
Chapter 7 describes our experience with IFN treatment in hepatitis B associated polyarteritis nodosa 
(PAN). Seven patients that developed PAN after (acute) hepatitis B infection were treated with 
prednisone and in four of these patients prednisone was combined with IFN. Among the four patients 
treated with a priming steroid course and IFN, three showed a clinical remission of PAN, and two 
cleared the infection altogether. None of the patients that received only prednisone exhibited a clinical 
remission or HBsAg seroconversion. Why some patients develop PAN in the course of acute hepatitis 
B infection remains unclear. We could not fmd any mutations in the HBV genome predisposing to 
PAN. The combination of short-term steroid priming followed by IFN appears to be an improvement 
over prednisone monotherapy. 
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At the start of the studies discussed in this thesis, effective control of the hepatitis B virus was only 
possible in a proportion of patients. With the introduction ofPEG-IFN and new powerful nucleoside 
analogues such as adefovir (approved recently), entecavir (phase III trials) and telbivudine (phase III 
trials), with a very small risk of resistance development, an adequate treatment for many chronic 
hepatitis B patients seems achievable. 
Conclusions: 
1. PEG-IFN is a safe and effective treatment for HBeAg positive chronic hepatitis B resulting in a 
sustained response in 36% of patients, which is associated with biochemical and histological 
improvement. The efficacy of PEG-IFN was not increased by combining PEG-IFN with 
larnivudine. 
2. The combination of PEG-IFN and larnivudine leads to a faster and more profound virus 
suppression during treatment compared to PEG-IFN alone. However this is not sustained after 
cessation of treatment. 
3. Patients who respond to standard IFN treatment have a decreased risk of developing hepatocellular 
carcinoma and a prolonged survival compared to non-responders. 
4. A priming course of prednisone followed by IFN appears to be beneficial in hepatitis B-associated 
PAN. 
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Samenvatting en conclusies 
Het doe! van de behandeling van cbronische hepatitis B is het voorkomen van levercirrhose en de 
complicaties daarvan. Ideaal zou zijn het geheel elimineren van het virus (HBsAg seroconversie). De 
meest gebruikte maat voor effectiviteit is echter controle van de virale replicatie, ofwel door 
(langdurige) onderdrukking met antivirale medica tie ofwel zonder medicatie na geslaagde 
immuunmodificerende behandeling. De afgelopen jaren is er sterke vooruitgang geboekt in de 
behandeling van cbronische hepatitis B. Bij de start van dit onderzoek in 1999 was de effectiviteit van 
de behandeling van cbronische hepatitis B nog beperkt. De twee toen geregistreerde middelen waren 
interferon alpha (IFN) en 1amivudine. IFN is slechts effectief in 20-35% van de patienten. De 
effectiviteit van behandeling met larnivudine wordt vooral beperkt door de opkomst van lamivudine 
resistente HBV mutanten. Daarom was er dringend behoefte aan effectievere 
behandelingsmogelijkheden. 
De hoge responspercentages die worden bereikt met gepegyleerde vormen van IFN bij patienten met 
cbronische hepatitis C hebben tot een hemieuwde belangstelling geleid voor IFN behandeling van 
cbronische hepatitis B. Wij bestudeerden het effect van peginterferon alpha-2b (PEG-IFN) in een grote 
gerandomiseerde studie, met deelnemende centra uit Europa, Azie en Canada. In totaa1 266 HBeAg-
positieve patienten werden geevalueerd na een jaar behandeling met PEG-IFN in combinatie met 
lamivudine ofp1acebo, en daama nog zes maanden gevolgd. Ons primaire eindpunt voor de studie was 
het verlies van serum HBeAg, omdat dit meestal gepaard gaat met duurzame virussuppressie en 
normalisatie van ALT. Wij vonden dat 36% van de patienten het serum HBeAg had verloren aan het 
eind van de follow-up periode (hoofdstuk 2). Hoewel het percentage patienten dat HBeAg had 
verloren aan het einde van de behandeling hoger was bij patienten die werden behandeld met de 
combinatie van PEG-IFN en larnivudine (44%) dan bij patienten die werden behandeld met PEG-IFN 
alleen (29%), bleef dit verschil niet behouden tijdens de vervolgperiode. Aan het eind van de 
vervolgperiode was er geen verschil in respons tussen patienten die werden behandeld met PEG-IFN 
aileen of in combinatie met larnivudine. De responspercentages werden mede bepaald door het HBV 
genotype, waarbij genotype A en B beter respondeerden dan genotype C en D. Omdat het HBV 
genotype een onafhankelijke voorspellende factor voor respons op behande1ing is, zal er in 
toekomstige studies rekening gehouden moeten worden met het genotype. Zoals bij cbronische 
hepatitis C, zullen mogelijk ook verschillende behandelingsschema's nodig zijn voor verschillende 
genotypes. 
Het effect van PEG-IFN op de histologie van de lever werd bepaald aan het einde van de behandeling 
bij 110 patienten. Wij vonden dat respons (HBeAg negativiteit aan het eind van de follow-up) op PEG-
IFN therapy ook vergezeld ging met histologische verbetering (hoofdstuk 3). Aan het eind van de 
behandeling was de necroinflammatie verbeterd bij de helft van de patienten, maar vaker bij 
responders (78%) dan bij non-responders (43%). Fibrose verbeterde aileen bij een minderheid van de 
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responders. Echter het interval van een jaar tussen de biopsieen is mogelijk te kort geweest om het 
volledige effect van de behandeling op de leverfibrose te bereiken. 
Met de combinatiebehandeling van PEG-IFN en larnivudine werd een snelle en sterke virussuppressie 
bereikt (hoofdstuk 4). Tijdens behandeling met PEG-IFN alleen was de daling van de hoeveelheid 
virus significant minder. Met name responders lieten een daling van de hoeveelheid virus zien, en bij 
een deel van de responders gebeurde dit pas na een variabele periode, die wel tot 32 weken kon duren. 
Wij bepaalden of de daling van het HBV DNA of het actuele HBV DNA niveau op individuele 
tijdspunten tijdens de behandeling gebruikt kon worden om respons te voorspellen. Wij vonden dat het 
HBV DNA niveau het beste geassocieerd was met respons. Vanwege de verschillende patronen van 
HBV DNA daling kon de beste predictie van respons gedaan worden op week 4 van de behandeling 
voor combinatiebehandeling met PEG-IFN en lamivudine, en op week 20 voor PEG-IFN alleen. De 
kans op respons was minimaal als bij de combinatietherapie van PEG-IFN en larnivudine het HBV 
DNA niveau na 4 weken behandeling nog boven 107 geq!mllag (negatiefpredictieve waarde 93%). Bij 
behandeling met PEG-IFN alleen was dit het geval als het HBV DNA niveau na 20 weken 
behandeling nog boven 109 geq!ml lag (negatief predictieve waarde 88% ). Deze grens zou dan ook 
aangehouden kunnen worden als "stopping rule". 
Omdat PEG-IFN behandeling niet eerder is onderzocht voor patienten met chronische hepatitis B, 
onderzochten we ook de veiligheid ervan in deze populatie patienten (hoofdstuk 5). De meest 
voorkomende bijwerkingen waren dezelfde als de bijwerkingen die optreden bij standaard IFN 
(griepachtige verschijnselen, hoofdpijn, vennoeidheid, spierpijn, haaruitva1, gastrointestinale 
verschijnselen en psychiatrische symptomen). Deze bijwerkingen waren vooral aanwezig gedurende 
de eerste maanden van de behandeling. Hematologische afwijkingen traden vaak op maar 1eidden niet 
tot emstige complicaties. Dosisreductie en stoppen met de behandeling was noodzakelijk bij 
respectievelijk 23% en 9% van de patienten. In de helft van de gevallen waar de dosis werd 
gereduceerd, gebeurde dit vanwege neutropenie, terwijl de meest voorkomende reden voor het stoppen 
van de behandeling het optreden van psychiatrische symptom en ( depressie, psychose) was. 
Neutropenie en levercirrhose bij het starten van de behandeling waren onafhankelijke predictoren voor 
dosisreductie en staken van de behandeling. Patienten met preexistente levercirrhose hadden een 
verhoogd risico op thrombocytopenie en (milde) bloedingscomplicaties. Alle bijwerkingen waren 
reversibel na staken van de behandeling. 
Hoewel de gunstige effecten van IFN behandeling op de ziekteactiviteit goed beschreven zijn, zijn de 
effecten op het ontwikelen van lange-termijn complicaties van levercirrhose en mortaliteit minder 
goed gedefinieerd. Daarom volgden we alle HBeAg-positieve chronische hepatitis B patienten die 
tussen 1978 en 2002 in Rotterdam werden behandeld met standaard IFN (hoofdstuk 6). De mediane 
follow-up duur in onze studie was 8,8 jaar. Van de 165 patienten patients respondeerden 33% op IFN 
behandeling, gedefmieerd als verlies van HBeAg tijdens behandeling of binnen een jaar na 
behandeling. Responders op IFN lieten een hoger percentage HBsAg verlies en minder progressie van 
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leverfibrose zien dan non-responders. Survival analyse liet zien dat het risico op het ontwikkelen van 
hepatoellulair carcinoom lager en de overleving beter was bij responders op IFN. 
Hoofdstuk 7 beschrijft onze ervaring met IFN behandeling bij hepatitis B geassocieerde polyarteritis 
nodosa (PAN). Zeven patienten die PAN ontwikkeleden na een (acute) hepatitis B infectie werden 
behandeld met prednison, en bij vier van deze patienten werd dit gecombineerd met IFN. Bij de vier 
patienten die kortdurend werden behandeld met prednison gevolgd door IFN lieten er drie een 
clinische remissie van de PAN zien en twee klaarden de infectie volledig. Geen van de patienten die 
alleen prednison kregen hadden een klinische remissie of HBsAg seroconversie. W aarom sommige 
patienten PAN ontwikkelen in het beloop van een acute hepatitis B infectie blijft onduidelijk. Wij 
konden geen mutaties vinden in HBV genome die predisponeren voor het ontwikkelen van PAN. De 
combinatie van kortdurende behandeling met steroYden gevolgd door IFN lijkt een verbetering ten 
opzichte van prednison monotherapie. 
Bij aanvang van dit onderzoek was slecht bij een deel van de patienten effectieve controle van het 
hepatitis B virus mogelijk. Met de komst van PEG-IFN en nieuwe krachtige nucleoside analogen als 
adefovir (recent geregistreerd), entecavir (fase Ill trials) en telbivudine (fase II trials), waarbij het 
risico op resistentieontwikkeling zeer gering is, lijkt een adequate behandeling bereikbaar voor veel 
patienten met chronische hepatitis B. 
Conclusies: 
L PEG-IFN is een veilige en effectieve behandeling voor HBeAg positieve chronische hepatitis B 
resulteerend in een blijvende respons bij 36% van de patienten, die geassocieerd is met 
biochemische en histologische verbetering. De effectiviteit van PEG-IFN wordt niet verhoogd 
door PEG-IFN met lamivudine te combineren. 
2. De combinatie van PEG-IFN en lamivudine leidt tot een snellere en sterkere virussuppressie 
tijdens de behandeling dan PEG-IFN alleen. Dit is echter niet duurzaam na het stoppen van de 
behandeling. 
3. Patienten die responderen op behandeling met standaard IFN hebben een verlaagd risico op het 
ontwikkelen van hepatocellulair carcinoom en een langere overleving vergeleken met non-
responders. 
5. Kortdurende behandeling met prednison gevolgd door IFN lijkt een gunstig effect te hebben bij 
hepatitis B-gassocieerde PAN. 
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Een promotieonderzoek is nooit het werk van een persoon. Ik heb het geluk gehad mee te mogen 
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veel mensen. 
Allereerst wil ik mijn promotor, professor Schalm, danken voor zijn grote inzet en gedrevenheid. 
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Mijn co-promotor Harry Janssen wil ik bedanken voor de begeleiding gedurende de studie. Dankzij 
jouw kritische blik waarmee je keer op keer de manuscripen hebt doorgenomen en het duwtje in de rug 
dat ik soms nodig had om verder te komen zijn de studies tot een goed einde gekomen. 
Rob de Man, bedankt voor de supervisie van de poliklinische patienten en het kritisch lezen van mijn 
manuscripten. 
De mensen van het trialbureau, Elke, Eva, Wanda en Maarten hebben zeer veel werk verzet bij het 
opzetten en begeleiden van de studie, en bij het ordenen en verwerken van de grote massa aan data. 
Bettina, bedankt voor de statistische analyses en de vele uren achter de computer! 
Dr. Zondervan, u heeft het histologie-artikel mogelijk gemaakt en mij tegelijkertijd een cursus 
leverhistologie gegeven! 
Zonder de monitors Mieke Denys, Sarah, Gerd, Anneleen en Kathleen, was het nooit gelukt een studie 
die in zoveel centra loopt in goede banen te leiden en aile data te verzamelen. Bedankt voor de fijne 
samenwerking en de gezelligheid op de congressen. 
De mensen van de CRU wil ik bedanken voor hun hulp bij de "visits" van de Rotterdamse patienten. 
Wilma en Karin, bedankt voor het bijhouden van aile CRF's. 
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Margriet en Marion, bedankt voor de hulp bij het submitten van de manuscripten en het "regelwerk" 
voor de promotie. 
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Nermin en Esther, het was een leuke tijd op de poli. Dank zij jullie liep het gesmeerd. 
De dames van het "kippenhok"- Heleen, Cockie, Anneke en Gwen: Bedankt voor de gezelligheid! 
Thjon, Jan-Maarten, Pieter, Rachel en Marjolein, heel veel succes met de opleiding. Wim, Hajo, Bart, 
Dave en Sarwa, jullie zijn al een eind op weg op het promotiepad. Succes, en ik kijk uit naar jullie 
boekjes! Annemiek, mijn kamergenootje, bedankt voor de gezelligheid en de vele kopjes thee. 
Tot slot wil ik de leden van de promotiecommissie bedanken voor het beoordelen van mijn 
manuscript. 
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APPENDIX The HBV 99-01 Study Group 
This thesis was based on the HBV 99-01 study. 
In addition to the authors of chapter 2-5, the HBV 99-01 Study Group includes the following 
investigators: 
The Netherlands: H.G.M. Niesters, P.E. Zondervan, B.E. Hansen (University Medical Center 
Rotterdam ), B.C.M. Vroom (University Medical Center Utrecht) C.M.J. van Nieuwkerk (VU 
University Medical Center Amsterdam), R.A. de Vries (Rijnstate Hospital Amhem), J. Jansen, 
J.Drenth, S.J.van den Hazel (University Medical Centre Radboud Nijmegen), J.W. den Ouden-Muller 
(St. Franciscus Hospital Rotterdam), A.C. Tan (Canisius Wilhelmina Hospital Nijmegen); Belgium: 
D.M. Adler (Hopital Erasme Brussels), P. Michielsen (University Hospital Antwerp), H. van 
Vlierberghe (University Hospital Gent), F. Nevens (University Hospital Leuven), J. Delwaide (Centre 
Hospitalier Universitaire Liege), J. Henrion (Hopital de Jolirnont, Raine St. Paul); Germany: S. 
Zeuzem (Saarland University Hospital, Homburg/Saar), G.Gerken, S Bein, U. Treichel (University 
Hospital Essen), J. Trojan (J.W. Goethe Universitat Frankfurt), M.P. Manns, J. Hadem (Medizinische 
Hochschule Hannover), C. Niederau (St. Jozef Hospital Oberhausen); Denmark: M.R. Buhl, I.M. 
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C. Simon (Medical University, Wroclaw), J. Cianciara, J. Jablonska, J Kozlowska (Medical Academy 
of Warsaw), D. Prokopowicz, R. Flisiak (Medical Academy of Bialystok), T. Mach (Collegium 
Medicum UJ Krakow); Spain: M. Buti, A. Valdes, R Esteban (Hospital Valle Hebron, Barcelona), M. 
Rodriguez, M. Garcia Espiga (Hospital Central de Asturias, Oviedo); Italy: A. Andriulli, G. 
Stomaiulo, G.B. Gaeta (Ospe. Gesu e Maria, Napoli), G. Montalto, F. D'Antona (Universita di 
Palermo); Greece: G.E. Kitis, P. Xiarchos Panagiotis (George Papanikolaou General Regional 
Hospital,Thessaloniki), N.C. Tassopoulos (West Attica Hospital Athens); Turkey: U.S. Akarca, G. 
Ersoz (Ege University Faculty of Medicine lzmir), S. Karayalcin, C. Yurdayin, H. Bozkaya (Medical 
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